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WHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 65 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1 See pages 113–19 for a full list of Witness Seminars held, details of the published volumes and other 
related publications.
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funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the Seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting. Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check 
his or her own contribution and to provide brief biographical details for an 
appendix. The editors incorporate participants’ minor corrections and turn the 
transcript into readable text, with footnotes, appendices, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2 See our group’s website at www.histmodbiomed.org 
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INTRODUCTION
That the phrases ‘Therapeutic Implications’ and ‘Muscular Dystrophy’ can 
occur in the title of this Witness Seminar should amaze those of us who began 
research on Duchenne muscular dystrophy in the pre-genomics world of the 
1960s and 1970s. It is worth recalling what research on Duchenne muscular 
dystrophy was like in that period, to provide context for the topic of this 
Witness Seminar.
Then, Duchenne muscular dystrophy seemed one of the most intractable of 
the inherited disorders. The natural history of boys with Duchenne muscular 
dystrophy was well defined, as was the X-linked pattern of inheritance. The 
pathological changes seen in muscle biopsies – muscle fibre degeneration, 
central nuclei, increased connective tissue – should have provided clues, but the 
biochemical processes underlying the condition were quite unknown. As A T 
Milhorat put it in the introduction to the 1973 International Symposium of the 
Muscular Dystrophy Association of America (MDA), ‘…we are quite unable 
to explain the mechanism of the underlying morbid process [in Duchenne 
muscular dystrophy], and we are impotent in our effort to treat the patient in 
any effective manner.’1
1 Milhorat (ed.) (1974).
Figure A: Professor Dubowitz’s laboratory members; back row from left: Brian Brown, Dorothy 
Ackroyd, Victor Dubowitz, Jan Witkowski, Joe Neerunjen; middle: Chris Webster,  Allie Moosa, 
Belinda Gallup; front: Christine Heinzmann, Elaine Woodcock, Bridget Lunn (Sheffield, 1972)
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I began research on Duchenne muscular dystrophy just one year before the 
1973 MDA conference. I had completed my PhD at the National Institute for 
Medical Research and for reasons no longer clear to me, I decided that I wanted 
to do research on Duchenne muscular dystrophy. There were three possibilities: 
Alan Emery in Edinburgh, Jack Sloper at Charing Cross and Victor Dubowitz 
at Sheffield. Edinburgh was a long way away, and as I didn’t want to stay in 
London, Sheffield it was. Moreover, I was an enthusiastic rock climber and 
living in Sheffield, with the Peak District at my doorstep, was irresistible. And 
Victor had a project that involved my specialty, cell culture. However, shortly 
after I accepted Victor’s offer, he wrote to tell me that he was coming south to 
take the Chair of Paediatrics at the Institute of Child Health at Hammersmith 
Hospital. Nevertheless, I spent the summer of 1972 in Sheffield learning about 
Duchenne muscular dystrophy and projects in the Dubowitz laboratory (Figure 
A), and in the evenings, climbing on a small crag on the bus route home.
At Hammersmith, Victor found temporary room for me in one of the buildings 
in the Labour Yard, an original part of the hospital dating from the time the 
hospital was a poor law institute. It was not until 1975 that the MDA funded the 
construction of a laboratory on the roof of one of the Hammersmith’s buildings. 
It was named after Jerry Lewis, chairman of the MDA and, appropriately, he 
came to open it (Figure B).
The profusion of hypotheses in the early 1970s regarding the pathogenesis of 
Duchenne muscular dystrophy underscores Milhorat’s remarks. As the Emerys 
describe in their book, The History of a Genetic Disease: Duchenne Muscular 
Dystrophy or Meryon’s Disease, these included the highly controversial neurogenic 
Figure B: Left to right: Dr Jan Witkowski, Professor Victor 
Dubowitz, and Mr Jerry Lewis (1975)
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hypothesis (largely espoused by Alan McComas, who claimed to find reduced 
numbers of motor units in a muscle of the foot), the vascular hypothesis (that 
was proposed to account for the clustering of degenerating fibres), and the 
myopathic hypothesis (that the defect was intrinsic to the muscle).2
The myopathic hypothesis had several lines of investigation, including 
biochemical and structural, and especially studies of the cell membrane. 
Examples from my box of reprints include: ‘Effects of Duchenne muscular 
dystrophy on muscle protein synthesis’, ‘Analysis of skin fibroblast proteins 
in Duchenne muscular dystrophy’, ‘Muscle fibre size and shape in Duchenne 
muscular dystrophy’, ‘A quantitative comparison of satellite cell ultrastructure in 
Duchenne muscular dystrophy, polymyositis, and normal controls’, ‘Distribution 
of freeze-fracture particle sizes in the Duchenne muscle plasma membrane’, and 
‘Human lymphocyte capping in Duchenne muscular dystrophy’.3
These indicate the wide range of investigations characteristic of that period and 
research in Victor’s laboratory was similar. Caroline Sewry pursued electron 
microscopic studies, Mike Dunn and Arthur Burghes used 2-D gel electrophoresis 
to analyse Duchenne muscular dystrophy cell proteins, Steve Appleyard worked on 
membrane freeze-fracture analysis, and Helen Statham studied calcium transport.
I was following up work that had been carried out in Victor’s Sheffield laboratory 
(Figure C). This research had shown that Duchenne muscular dystrophy muscle 
2 Emery and Emery (2011).
3 Burghes et al. (1982), Fischbeck, Bonilla, and Schotland (1984), Horenstein and Emery (1980), Rennie 
et al. (1982), Watkins and Cullen (1982, 1986).
Figure C: Dr Jan Witkowski (1975)
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cells in culture were indistinguishable from those derived from normal muscle. This 
suggested that the Duchenne muscular dystrophy defect was not cell autonomous 
and that, perhaps, the myotubes in culture did not differentiate sufficiently far for 
a Duchenne muscular dystrophy phenotype to manifest itself. So I co-cultured 
human muscle cell cultures with slices of mouse embryonic spinal cord, to no 
avail. Similar work was going on elsewhere, but this isn’t the place for an exhaustive 
account. Also, I sent cultures (by mail!) to Alan Harvey at Strathclyde, who carried 
out electrophysiological measurements, but again, finding no differences between 
normal and Duchenne muscular dystrophy myotubes.
I then turned to the membrane hypothesis and made measurements of cells 
moving in cultures of human muscle but found no differences, perhaps because 
there was no way of distinguishing between myoblasts and fibroblasts. Gareth 
Jones and I carried out measurements of intercellular adhesion, using a Couette 
viscometer, a technique at which Gareth excelled. One drawback was that we 
had to use cells of uniform shape and size and this precluded using muscle cells. 
Instead we used skin fibroblasts on the grounds that if there was a ‘generalized’ 
muscle defect, skin fibroblasts might show some effects. In blinded experiments 
we did find differences, but the significance of these is obscure. Finally, Helen 
Statham and I carried out experiments on protein degradation, measuring the 
rate of protein turnover. We used skin fibroblasts to develop the technique, 
intending to apply it to muscle cultures, but circumstances overtook us.
Those circumstances were the development of gene mapping using restriction 
fragment length polymorphisms (RFLPs) in 1980 and its application to Duchenne 
muscular dystrophy in 1982. This has already been covered in the Witness Seminar 
on Human Gene Mapping Workshops c.1973–c.1991,4 and the clinical significance 
of cloning the dystrophin gene complementary DNA (cDNA) and its application 
in diagnosis was emphasized by John Yates in the Witness Seminar on Clinical 
Molecular Genetics in the UK c.1975–c.2000.5 It was not that everything was now 
plain sailing, as I was sharply reminded by Bud Rowland. In 1988 I wrote a short 
essay with the title ‘The molecular genetics of Duchenne muscular dystrophy: the 
beginning of the end?’6 Bud wrote a similar article for the New England Journal of 
Medicine and used ‘…the end of the beginning’.7
4 Jones and Tansey (eds) (2015).




Figure D: Dr (later Professor Dame) Kay Davies at the meeting ‘Dystrophin’ at the 
Banbury Center, Cold Spring Harbor Laboratory (CSHL), in 1989.  
Dr Gert-Jan van Ommen is on the left and Dr Lou Kunkel on the right
(A personal aside. RFLP mapping changed my life too. We had a collaboration 
with Bob Williamson and Kay Davies (Figure D) at St Mary’s. One day in 
1983 Kay and I were in a pub near St Mary’s and Kay told me that if I wanted 
to stay in human genetics, I had to go molecular. So I applied for a Medical 
Research Council (MRC) training fellowship in recombinant DNA techniques 
and I spent two years with Gordon Peters at Imperial Cancer Research Fund 
learning the techniques (Figure E). Tom Caskey at Baylor College of Medicine 
invited me to run his DNA diagnostics laboratory and I can still remember the 
thrill of using the phenol-emulsion reassociation technique (PERT) clones from 
Lou Kunkel’s laboratory for prenatal diagnosis and seeing deletions. Such an 
advance over linkage analysis! Then Jim Watson recruited me to the Banbury 
Center where I kept in contact with Duchenne muscular dystrophy by holding 
several meetings on the topic.)
Of course Bud was right. An immense amount of work remained to be done, 
but once the gene and protein had been identified, the intense but diffuse 
research spread across many approaches became focused on analysing the gene 
and discovering what dystrophin did in the cell. It required advances in many 
other areas of molecular genetics and biochemistry to develop the therapeutic 
strategies discussed in this Witness Seminar. 
xx
Figure E: Announcement of Jan Witkowski’s MRC special training fellowship  
(Medical Research Council Newsletter, 1984)
Figure F
There was much discussion of one particular therapeutic strategy, exon skipping. 
Just one year after the Witness Seminar, that therapeutic strategy became a 
reality, when, in September 2016, the Food and Drug Administration approved 
Exondys 51. Although a decision that has generated great controversy, it is a 
testament to the extraordinary efforts of families, scientists, and physicians who 
have contributed to the research, that Duchenne muscular dystrophy, once the 
most intractable of inherited genetic disorders, now has a treatment.
Professor Jan A Witkowski
Watson School of Biological Sciences,  
CSHL Graduate School  
& Banbury Center, CSHL
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Professor Tilli Tansey:  Welcome everyone to this Witness Seminar on the 
Therapeutic Implications of Muscular Dystrophy Genomics. I’m Tilli Tansey 
and I run these Witness Seminars where we get together a group of people 
who have been involved in a particular discovery or event to discuss what really 
happened, what went right, what went wrong, who were the movers, because 
history is not inevitable and some of the events actually happened because of 
serendipitous events or just chance encounters. I know there are some people 
here who have been to a number of our meetings before and it’s very nice to see 
you back at this meeting. This is about the sixth that we’ve held on the topic 
of clinical genetics, and we’ve recently just published a meeting on the Human 
Gene Mapping Workshops.1 Everything we do is freely available online on our 
website.2 We’ve provided a broad outline of discussion points, but you may feel 
there are avenues you wish to explore that are not included.3 
This meeting came about at the suggestion of Professor Steve Sturdy, who 
heads a group in the University of Edinburgh on ‘Making Genomic Medicine’. 
He is funded by a Senior Investigator Award of the Wellcome Trust and it’s 
1 Jones and Tansey (eds) (2015).
2 The History of Modern Biomedicine Research Group’s website is: www.histmodbiomed.org (accessed 11 
January 2017).
3 A draft outline programme was circulated to seminar participants to comment on a month in advance of 
this meeting. Table 1 is the final version of that programme used as a framework for this seminar.
Figures 1 and 2: Professor Karen Temple and Professor Tilli Tansey
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Steve’s idea, and some of his team who are also here today, to have this Witness 
Seminar to get behind the science and the published papers. A key part of any 
of these seminars is identifying a suitable chairman and I’m delighted that we’ve 
been able to persuade Karen Temple to come and chair, or facilitate, and guide 
you all through this process. Karen is the Professor of Medical Genetics at the 
University of Southampton and she is the Director of the Academic Unit of 
Human Development and Health, heading a large group of clinicians, scientists, 
and students. So, without further ado, I’m going to hand over to Karen.
Professor Karen Temple:  Thank you very much. I hope first of all that you 
can hear alright because it is rather a big room. We’ve got to imagine that this 
is a very intimate gathering where we can actually say how it was when we were 
young, if you like. We’re going to start in the 1970s, or at least around that sort 
of time, to try to get an idea of how it was before we knew where this massive 
Introduction to ‘Making Genomic Medicine’
History, medical, and scientific knowledge of 
muscular dystrophy
• Muscular dystrophy before molecular diagnostics 
•  Discovery of DNA markers: lab–clinic 
collaboration 
•  Clinical use of markers:
•  circulation of diagnostic probes
•  prenatal testing 
•  carrier testing
•  Sequencing the gene
•  Commercial dimensions:
•  diagnostics
•  therapeutics 
•  International collaborations:
•  reference networks
•  biobank projects
•  From management to therapy: development of 
gene-skipping therapy
Table 1: Witness Seminar outline programme
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gene for Duchenne muscular dystrophy lived, as it were.4 Now I have to say that 
I think one of the reasons that I am the chair is that I let on during a talk at the 
Genetic Alliance UK5 that I was old enough to have used the restriction fragment 
length polymorphisms (RFLPs) in clinical practice in the late 1980s, and I can’t 
tell you how exciting it is for me to have you all sitting here in this room with 
the opportunity to tell us how it was. So that’s really your job. What’s likely to 
happen is that someone will say something and that will make you realize, ‘Oh 
yes, I remember that.’ And that’s exactly what we’re trying to capture because so 
much of what we write is somewhat sterile and we’ve really got to try to work out 
and remember how it was. So who feels brave enough to kick this off because 
what we want to know is, what did we do before we knew where the gene was, 
and how did this adventure start? Because it really was one of the first genes to be 
cloned. So who feels that they could start off for us? Victor.
Professor Victor Dubowitz:  Hello, I’m Victor Dubowitz, pensioner. My recent 
memory is not very good, but my long-term memory has become sharper.
I’ll go a little bit further back than the 1970s to the 1950s when I first got 
interested in muscular dystrophy while a short-term locum resident at Queen 
Mary’s Hospital for Children, Carshalton, where there were two full wards with 
long-stay muscular dystrophy and other muscle diseases. I’d never heard of it 
before and so the impact, in fact, of the clinical picture is a very striking one. 
Now if you can imagine what it was like from a diagnostic point of view before 
there was any creatine kinase (CK), that’s the blood enzyme that’s now done 
routinely.6 If suspected, they’d get transaminases done and then many of these 
children ended up with a liver biopsy because the doctors thought the abnormal 
transaminases suggested liver disease. 
4 Duchenne muscular dystrophy is an X-linked recessive form of muscular dystrophy, resulting in muscular 
degeneration and premature death. The disease occurs at a frequency of about 1 in 3,500 newborn males, 
and is caused by a mutation in the dystrophin gene. The latter is located at locus Xp21 (on the short arm 
of the X chromosome). The dystrophin gene is the largest gene found in nature, measuring 2.4 megabases 
(Mb); see www.ncbi.nlm.nih.gov/gene/1756 (accessed 11 January 2017).
5 The Genetic Alliance UK is an umbrella charity for over 150 voluntary patient organizations for genetic 
diseases in the UK, supporting patients affected by all types of genetic conditions and their families. It 
was founded in 1989 as the ‘Genetic Interest Group’ and changed to its current name in 2010; see www.
geneticalliance.org.uk/index.html (accessed 11 January 2017).
6 Creatine kinase (CK; EC 2.7.3.2) is an enzyme catalyzing the conversion of creatine to phosphocreatine, 
with the utilization of adenosine triphosphate and the production of adenosine diphosphate. Increased 
amounts of CK in the blood could arise from muscular damage, thus CK is a routinely assessed marker for 
myocardial infarction and myopathies, including those of muscular dystrophies.
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From a clinical point of view the parents often became worried in the first year 
of life. They said the child’s a bit ungainly, not quite up to the other siblings, 
and then in the second year they had difficulty going up steps, about half 
of them were late walking, and so the parents were getting worried. But the 
doctors, as usual, reassured them: ‘Don’t worry, the child’s lazy, will grow out 
of it,’ and so on. So diagnosis was often delayed till the age of five or six or 
thereabouts, unless there was a previous affected child in the family, then very 
often the doctors would listen to parents and do the checks. So that’s more or 
less a picture from a diagnostic point of view. Perhaps that’s enough from me for 
the moment, but if you want a picture of the disease I can do that a little later. 
Temple:  Well, who better to do it? How did you diagnose Duchenne patients?
Dubowitz:  Well, it affected them in a number of ways. Firstly there was late 
diagnosis so by the time they were diagnosed they were usually five or six or 
seven years of age, and then they realized when they went to school and were 
not keeping up with the other children. They could never run at all and they had 
frequent falls as if their legs were just pulled out from under them, and difficulty 
getting up, and with the usual classical Gowers’,7 which people then started to 
recognize. This was also an age of neglect, in which specialist doctors to which 
7 Gowers’ sign indicates muscular weakness through the pattern of rising from the floor from a squatting 
position; typical for patients with muscular dystrophy, and named after a neurologist Sir William Gowers 
(1845–1915). For more details, see Chang and Mubarak (2012).
Figure 3: Professor Victor Dubowitz
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they were referred would make a diagnosis, sympathize with the family and say: 
‘I’m terribly sorry, there’s nothing we can do, just make the child comfortable.’ 
And then they ended up with the most grotesque deformities, which are 
unbelievable now. Imagine children who couldn’t even sit because they had 
such a bad S-shaped scoliosis that they were bed-bound, and couldn’t get into 
shoes because the feet were totally twisted round and so on. And then it was 
fortunate that at Queen Mary’s, Carshalton, where I’d worked, there was a polio 
epidemic. Well, not fortunate for the children, but 1956 was the last big polio 
epidemic8 and they had a very good facility for physiotherapy/rehabilitation. 
They were doing the Kenny techniques,9 and they were providing these children 
with special appliances and jackets and things, and then it seemed obvious that 
the muscular dystrophy children could benefit, and so there was a lot of interest 
in doing that. And they were very inspired because it cost nothing. The nursing 
sister on the unit had realized there was a celluloid factory nearby and had 
got all the offcuts of celluloid for free, dissolved it in acetone, painted it on to 
muslin, put the muslin on to the kids and when it dried they had an absolutely 
firm hard, lightweight shell. Couldn’t improve on that. 
So that was a bit of a supportive thing preventing severe deformities and also, 
for paediatricians in a sense, it was such a rare disease that they never heard of 
it basically. The neurologists said, ‘Well, it’s a little bit beyond the liver system; 
you know, the central nervous system ended at the intramuscular junction, so 
muscle disease was also a bit peripheral so there was nobody who was really 
taking it on as a primary interest.’ 
Temple:  Because it was so rare really for any one individual to see many cases?
Dubowitz:  In a sense they were a sort of ‘Cinderella’ of every profession, a bit too 
peripheral for the neurologists and a bit too rare for the paediatricians. Now the 
first thing that happened actually was that there was an enzyme, aldolase, which 
was first found, and one of the enthusiasts at that time was Brian McArdle, who 
described McArdle’s disease.10 In fact he was at Guy’s at the time when I linked 
up with Guy’s because Queen Mary’s, Carshalton, had a student group that 
8 For more details, see Gould (1995), Smallman-Raynor and Cliff (2014), as well as discussion in Reynolds 
and Tansey (eds) (2011).
9 Sister Elizabeth Kenny (1880–1952) was an Australian nurse who invented an innovative (yet 
controversial) treatment for polio; for more details, see Cohn (1976). 
10 Dr Brian McArdle (1911–2002) was a neurologist at Guy’s Hospital, London, who described ‘McArdle 
disease’ (a type V glycogen storage disorder) in 1951; see McArdle (1951).
The Therapeutic Implications of Muscular Dystrophy Genomics
8
used to come out and then in no time he was doing enzymes for us. And this 
aldolase was a very good discriminative one. Then of course CK came in about 
the late 1950s – 1959, 1960 – from Ebashi,11 who was a brilliant biochemist in 
Japan, and he found that it was extremely high in muscular dystrophy and that 
it was specific to muscles so it was influenced by liver disease. That was a major 
development. Then, of course, the pathology was fairly distinctive, but it was 
again delayed very often. But with the CK you could, and now CK has become 
a sort of potential marker at birth pre the genetic revolution. Now, of course, it’s 
much simpler to do a whole genome than to do a CK. 
Temple:  Well, I don’t know about that sometimes [laughter]. What about the 
fact that it was raised in women? Was that something people remember? 
Dubowitz:  What, about the X link? Yes, well Meryon actually. Meryon was a 
British physician who, in 1851, gave a very detailed description of Duchenne 
muscular dystrophy, some 16 years ahead of Duchenne.12 It should really be 
called ‘Meryon’s disease’. Alan Emery did a book on Meryon13 and we did an 
annotation in the European Journal of Paediatric Neurology on Meryon’s disease 
just to put it into the literature.14 He said that it is a disease that specifically 
affects boys, but seems to be transmitted by women. 
Temple:  And that was well recognized?
Dubowitz:  That’s been well recognized over the years, yes. When I worked in 
Sheffield in the 1960s, I was very sensitive to the family situations and I soon 
started taking blood from both the mothers and the fathers. Because if you only 
took it from the mother and you found she was a carrier, the next thing was the 
father said: ‘I told you your family had bad blood.’
Temple:  Yes, I used to do that as well, take it from both.
Dubowitz:  I then used to tell the fathers: ‘It is your fault that your daughters 
are carriers because you are responsible for giving her an X chromosome instead 
of a Y.’ So there’s all sorts of nuances in science, and sometimes you’ll get a 
11 Okinaka et al. (1964). Professor Setsuro Ebashi (1922–2006) was Professor of Pharmacology and of 
Biophysics at the University of Tokyo, Japan; for more details, see Otsuka (2007).
12 Meryon’s description of the disease was read at the Royal Medical & Chirurgical Society on 9 December 
1851, but was reported the year after: Meryon (1852). For more details, see Emery and Emery (1993).
13 Emery and Emery (2011).
14 Dubowitz (1998).
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surprise. We had one father who came with his classical Duchenne child to the 
clinic one morning and the child’s CK was sky-high and the father’s was also 
very high, around 2,000 units. So we were a bit puzzled because it was classical 
Duchenne. Then, taking his history, he’d actually been working on a clay mine, 
a clay pit, so we told him to come again after he’d had a day or two’s rest and his 
CK was normal. So exercise pushes CK up.
Temple:  Of course, that was what we were always told, that we had to take that 
CK at a time when someone had had a period of rest. 
Dubowitz:  That’s right, excepting in carriers. Because if you exercise female 
carriers, or potential carriers, it may be normal at rest and then you get an 
abnormal rise during exercise. 
Temple:  Oh, I didn’t know that. So who created those curves? The CK curves? 
Was that you?
Dubowitz:  Well, actually the European method for CK, now that I come to 
think of it, was actually standardized by the Head of Biochemistry for many 
years at the Hammersmith, David Moss. He actually did a European standard, 
and he was trying to standardize the method at the time.15
Temple:  Because all of us who were in genetics at that time would have those 
curves on our wall, because you had to work out what their risk factor was.
Dubowitz:  There’s always a difficulty, you see, of any sort of standardization 
because this is just the way the world is outside of muscular dystrophy. But one 
of the normal controls that the biochemist had done was that of a PhD student 
in his lab. She had a CK of about 1,500 and she had no obvious weakness, 
perhaps a bit of wasting in the shoulder, and so we weren’t quite sure whether 
she was a potential Duchenne carrier or a potential limb-girdle muscular 
dystrophy case.16 Eventually it turned out that she was a carrier, because she 
fell pregnant and, in fact, I think, it was already at the stage that you could do 
prenatal chorionic villus biopsy. 
Temple:  That’s very interesting. So, can we hear from some of the other people 
about how we found the gene, for example?
15 Moss et al. (1981).
16 Limb-girdle muscular dystrophy is a group of rare muscular dystrophies characterized by progressive 
muscular wasting that primarily affects muscles of the shoulder and the hip.
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Professor Gert-Jan van Ommen:  Well, I think that at some point DNA 
came in and one person that played a part there in parallel to Bob Williamson 
and Kay Davies here in the UK,17 was our boss Peter Pearson, who originally 
was a cytogeneticist toying around with microscopes and developing staining 
technologies.18 At some point in the late 1970s when the first non-causal but 
linked polymorphism was connected to a disease – that was the Kan and Dozy 
paper for sickle-cell anaemia,19 and some papers right after that – he realized 
that by using segments of DNA you could actually count chromosomes, or 
count pieces of chromosomes. Perhaps I should give the microphone now to 
my colleague, Bert Bakker, because I wasn’t in the laboratory then, but I heard 
it from what he told us: that he really then realized that by just picking out 
pieces of DNA and cloning them, you could actually make probes for specific 
parts of chromosomes, and in this way count. So he wasn’t originally focused on 
Duchenne. He came from a cytogenetics point of view; he was looking at DNA 
as a way to measure chromosomes in a very refined fashion. And I think that 
17 Professor Bob Williamson was Professor of Molecular Genetics and Biochemistry at St Mary’s Hospital 
Medical School, University of London and is Honorary Professor of Medical Genetics at the Murdoch 
Institute, the University of Melbourne; https://www.mcri.edu.au/users/professor-bob-williamson (accessed 
10 February 2017). He wrote the introduction to Jones and Tansey (eds) (2014). Professor Dame Kay 
Davies is Dr Lee’s Professor of Anatomy and Director of the MRC Functional Genomics Unit at the 
University of Oxford; for more details, see www.dpag.ox.ac.uk/team/kay-davies (accessed 11 January 2017).
18 For more details, see Jones and Tansey (eds) (2014). 
19 Kan and Dozy (1978).
Figure 4: Professor Gert-Jan van Ommen
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it was through a good friend and colleague, Martin Bobrow,20 well known to 
you I would assume, and Ysbrand Poortman,21 the leader of the Dutch patient 
organization, that he got interested in the Duchenne field. 
Temple:  So how did that come about?
van Ommen:  Well, Bert can say that better than I can.
Professor Bert Bakker:  Thank you. I’m Bert Bakker, also from Leiden. At the 
end of the 1970s, Peter Pearson had seen this paper of Kan and Dozy with the 
RFLP around the β-globin gene.22 Using this type of RFLP, he thought if he 
could have more of these probes, or not the β-globin gene but other pieces of 
DNA, looking for restriction fragment variation, you could saturate the human 
map with these kinds of polymorphisms and follow diseases in families. That 
was the idea.
Temple:  Had anyone else done this? Was that a novel idea?
Bakker:  Of course it was known from the β-globin gene that it segregates and 
that you can use it, but then to really go and look for them randomly was maybe 
new. Botstein also wrote about these genetic markers around the same time,23 
but Peter Pearson came into the lab and said to me: ‘Okay, let’s make these 
probes.’ There was nothing. So I had to go to the maternity ward, get a placenta, 
and from this human placenta, isolate the DNA, and digest it in small pieces 
using EcoRI restriction enzyme.24 At that time we had to isolate these restriction 
enzymes ourselves by growing the bacteria, isolating the enzyme through 
columns, and things like that. That was a lot of work but anyway we had these 
pieces of DNA digested, visualized as a smear on an agarose gel – it looked nice, 
but then we needed more to clone them. So it (more digested DNA) was run on 
a sucrose gradient to pick out pieces of 1 kilobase (kb), 2 kb, and 3 kb, and these 
20 Professor Martin Bobrow is a medical geneticist who has served as Professor of Medical Genetics at the 
University of Cambridge; for more details, see his profile at the Royal Society website: https://royalsociety.
org/people/martin-bobrow-11104/ (accessed 11 January 2017).
21 Mr Ysbrand Poortman is the founder of the Dutch Neuromuscular Diseases Association, and of the 
Dutch Genetic Alliance of Parent/Patient Organizations; for more information, see the respective websites: 
www.vsn.nl/ and www.vsop.nl/nl/ (both accessed 11 January 2017).
22 See note 19.
23 Botstein et al. (1980).
24 EcoRI is a restriction endonuclease enzyme deriving from Escherichia coli, and an invaluable tool in a 
variety of molecular genetics techniques, including cloning, DNA screening, and deleting DNA sections.
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pieces were ligated into a plasmid. The ligation into a plasmid was not possible 
at that time in the Netherlands because the law prohibited us cloning these 
human fragments in bacteria; that was not allowed at that time.25 A few years 
later it was, but in the meantime we could go to Mill Hill, to the lab of Dick 
Flavell,26 who formerly worked in Amsterdam, and there I had learned Southern 
blotting before the RFLP time. So I went to Mill Hill National Institute for 
Medical Research to clone these fragments (random pieces) of human DNA in 
a plasmid (pAT153), put them on a plate, picked them out, and then sorted 
them to see if they were repetitive or non-repetitive.27 
Temple:  How did you make that collaboration with Mill Hill? Was everyone 
friends with each other?
Bakker:  Yes, yes. Because we had already collaborated before that with some 
of the people, the whole group actually from Amsterdam moved to Mill Hill, 
because the cloning was not possible in the Netherlands. Dick Flavell wanted 
25 For more details, see Professor Bert Bakker’s video interview (clip 3) at the History of Modern Biomedicine 
Research Group’s website: www.histmodbiomed.org/article/bakker-bert (accessed 11 January 2017).
26 Professor Richard Anthony Flavell is Sterling Professor of Immunobiology at Yale University School of 
Medicine. He was at the University of Amsterdam from 1974 to 1979 and was then Head of the Laboratory 
of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill (1979–1982); for 
more details, see http://immunobiology.yale.edu/people/richard_flavell.profile (accessed 11 January 2017).
27 For more details on Professor Bert Bakker’s work at Mill Hill, see Jones and Tansey (eds) (2014), pages 
10–12. 
Figure 5: Professor Bert Bakker
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to clone and work together with Alec Jeffreys,28 so he moved to Mill Hill to do 
it there. Then I sorted these probes by hybridizing them back to human DNA 
to see if they were repetitive or not repetitive, and hybridizing them to different 
pieces, different digestions of human DNA, so PstI, TaqI, or BglII, and all the 
different enzymes hybridize them back to the DNA and detect polymorphisms. 
So I saw these RFLPs and, in this one experiment, I had 23 unique probes on 
the human gene map. 
Temple:  They were all over the place?
Bakker:  All over the place, but then later we had to sort them on the chromosomes 
they were on, of course. One of them (L1.28) appeared to be on the X chromosome 
because we saw it was polymorphic: one son had one allele, the other son had the 
other allele, mother was heterozygous – so we did the whole series and it did fit. 
All boys had one allele and all females had two alleles, so we could say: ‘Okay, 
this is probably on the X chromosome.’ Later, by using somatic cell hybrids we 
could show that it was on the short arm of the X chromosome, and it was about 
the same time that Kay Davies in London, with her group and Rob Elles, had 
cloned this RC8 probe,29 which was on the other side of the short arm of the 
X chromosomes. These two together flanked the region where Duchenne was 
supposed to be, because there were girls with Duchenne muscular dystrophy 
where there was a translocation on the X chromosomes, and we knew that the 
break in the X chromosomes was in the middle of the short arm. 
Temple:  So who found those girls? Can you remember?
Bakker:  I think at that time, there were about 10 or 15 different girls known 
to have Duchenne muscular dystrophy, and it was known that there was a 
translocation on chromosome analysis, all rare cases, of course. 
28 Professor Sir Alec Jeffreys is Professor of Genetics and Royal Society Wolfson Research Professor at the 
University of Leicester. For more details, see www2.le.ac.uk/departments/genetics/people/jeffreys (accessed 
11 January 2017).
29 Professor Andrew Read, who is Emeritus Professor of Human Genetics at the University of Manchester, 
explains that the ‘R’ in the ‘RC8’ probe came from the initial of the name of Rob Elles; see his oral history 
interview, available on the Genetics and Medicine Historical Network website; https://genmedhist.eshg.org/
fileadmin/content/website-layout/interviewees-attachments/Read,%20Andrew.pdf (accessed 11 January 
2017). Dr Rob Elles (b. 1951) was a technician in Bob Williamson’s lab in St Mary’s Hospital from 1977 to 
1983, where Professor Dame Kay Davies undertook her early work on the X chromosome and developed a 
library of cloned sequences of the human X chromosome; Davies et al. (1981). Among the clone sequences 
in the library, RC8 was later discovered to be linked to Duchenne muscular dystrophy; Murray et al. (1982). 
For more details on Dr Rob Elles, see Jones and Tansey (2014), pages 102–3.
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Temple:  And were they cell-lines you could study?
Bakker:  Yes, we had some of these cell-lines in the lab to study.30
Temple:  And do you know who gave them to you?
Bakker:  We had different collaborators on that. We can go back to that.31
Temple:  Do you think it was easier then to collaborate?
Bakker:  Yes, it was easy to collaborate.32 
van Ommen:  I think that one of these cases was notably quite famous, and 
that was the one that was discovered by Christine Verellen in Belgium and was 
studied together with Ron Worton and Peter Ray in Toronto, and that was an 
X:21 translocation.33 There were indeed a number of these cases, but that was the 
specific one that Ron started working on, moving from the chromosome 21 area 
into the X chromosome area. But that was a few years later. In the beginning, 
when we were talking about the two probes that Bert talked about, RC8 from 
Kay Davies and L1.28 from Leiden, that must have been late 1982. The first 
paper was in 1982 by Murray with Kay Davies and Bob Williamson for RC8,34 
and 1983 was the joint paper with Peter Pearson for the carrier detection.35
Temple:  So you had, by that stage, shown it in Duchenne families?
Bakker:  No, Duchenne came in a little bit later, so the probes were there 
(in 1981) and the first meeting that Peter Pearson went to with these 
probes, to show that they existed, was in Oslo at the Human Gene Mapping 
conference.36 A little later in the same year, also 1981, there was a meeting in 
30 Professor Bert Bakker commented: ‘There was an earlier project where Peter Pearson investigated the 
position effect of autosome translocations to the X chromosome and the spreading of gene activation/
inactivation in the autosome part by using somatic cell hybrids; Pearson et al. (1978).’ Note on draft 
transcript, 10 February 2016.
31 For a list of the then available cell-lines, see: Bakker (1989).
32 Professor Bert Bakker added: ‘Peter Pearson had good contacts.’ Note on draft transcript, 10 February 
2016.
33 Verellen et al. (1977).
34 Murray et al. (1982).
35 Davies et al. (1983).
36 The Sixth International Workshop on Human Gene Mapping took place at the University of Oslo (29 
June to 3 July 1981). For more details, see Berg (1982).
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Israel, Tel Aviv,37 and there he met Ysbrand Poortman. Ysbrand Poortman was 
from the patient organization, the muscular dystrophy organization in the 
Netherlands,38 and he said to Peter: ‘You should work on Duchenne muscular 
dystrophy. If you have a probe on the X chromosome, you should work on 
Duchenne muscular dystrophy.’ And he convinced Peter because he came 
back from this meeting in 1981, and Peter said: ‘We’re going to work on 
Duchenne muscular dystrophy.’ 
Temple:  So that was patient power?
Bakker:  And then a clinical geneticist, Henk Venema,39 was just starting in the 
lab – because clinical genetics was just starting in the early 1980s – and he 
then, early 1982, went to all the different families to collect lots of samples. 
With these we could start doing linkage in the families and show that we could 
do carrier detection. That was 1983,40 and at the end of 1984 we did the first 
prenatal diagnosis.41
Temple:  Before that, you had no idea that your RFLP was going to be important 
for Duchenne? It was just on the X.
Bakker:  Yes, it was on the X and it was close to RC8, flanking Duchenne 
muscular dystrophy, that’s what we knew, but that we had to work on Duchenne, 
that came through this meeting with the patient organization, with Ysbrand 
Poortman.
Temple:  That’s really special, isn’t it? So then you started finding out how your 
probe would make a difference to families?
37 The Sixth International Congress of Human Genetics took place in Jerusalem, Israel (13–18 September 
1981).
38 See note 21.
39 Professor Bert Bakker commented: ‘Henk Venema, in 1987, was one of the first registered clinical 
geneticists in the Netherlands. After a successful career (1960–1980) as general practitioner in Dordrecht, 
Venema came to Leiden University where he started as a genetic counsellor at the Clinical Genetic Centre, 
and as a researcher at the Department of Human Genetics. In 1989 Venema produced his PhD Thesis 
entitled: Clinical, cytogenetic and molecular aspects of the fragile-X syndrome.’ E-mail to Dr Apostolos Zarros, 
19 January 2017.
40 Wieacker et al. (1983).
41 Bakker et al. (1985).
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Bakker:  Yes, this one probe was only informative in about 10 per cent of the 
families, and that was not enough, so we needed more of these probes. That’s 
why Peter Pearson hired a new PhD student, Marten Hofker,42 who came into 
the lab and who was dedicated to make more probes on the X chromosome. He 
made a phage λ library to produce more of these probes. From that series came 
754 and 782 probes, which are also close to Duchenne muscular dystrophy.43
Temple:  Were you working with Professor Williamson at that point, or was he 
doing something else?44
Bakker:  We were working together. We exchanged the probes, so our probes 
went to them and they sent us their probes. Actually by giving all these 23 
probes that we had, so sharing these with other laboratories, we got other probes 
back. And from the other probes we could fill up the map, and also in the 
Duchenne gene, we got enough probes to do reliable diagnosis.
Professor Steve Sturdy:  Can I ask, just to get a sense of the larger picture that 
this was part of: you had 23 probes, I think you said – did you just home in on 
Duchenne or did you look for other possible diseases that you might conduct 
linkage studies on as well? Was it just by chance that Duchenne fell out of this?
42 Professor Marten Hofker (1956–2016) was Professor of Molecular Genetics at the University of 
Groningen; for his obituary, see de Winther, Dallinga-Thie, and Kuipers (2017).
43 Hofker et al. (1985).
44 See note 17.
Figure 6: Professor Steve Sturdy
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Bakker:  It was by chance that Duchenne fell out of this, but the other probes 
were used for other diseases, of course, and there were some on chromosome 
16 and chromosome 2. One of the probes on chromosome 2 was at the tip 
of chromosome 2, and we had localized that by using in situ hybridization. I 
did one on the first in situ hybridization assays by using tritium on the tip of 
chromosome 2, but we didn’t know how correct that was. I told Peter Pearson 
that I didn’t know if it was really localized there. So we kept it until the acetate 
phosphatase gene was found on the tip of chromosome 2 and it was published, 
or it was published later,45 and Peter said: ‘Okay, let’s use the probe’ and we 
published, together with people in Oslo. So there are more probes that are used 
later in all kinds of diseases.
Sturdy:  And were other people picking up as early as this on the opportunities 
that RFLP probes offered? I’d be interested to hear how other people were 
working?
Bakker:  Other groups started, of course. Many of these probes were produced 
by laboratories within a few years.
Temple:  Any American experience?
van Ommen:  There was a probe called ‘C7’ and a few more. Actually, the 
generation of these probes was really in hot pursuit and, as Bert said, that field 
in those days was, I think, one of the most sharing fields that I have known, 
because, really, by yourself you didn’t have anything, because everybody had 
only a pathetic amount of families.
Temple:  It’s just the same now!
van Ommen:  Actually, by sharing these things around you found out that 
not only could you help other people, but yes, indeed, you sometimes became 
author of a paper on a disease that you hadn’t heard of the day before. It was 
really a very funny type of field. There was a time, I think in 1984 or so, when 
these ‘L’ probes, the Leiden probes, were actually constituting 40 per cent of all 
the known polymorphisms on the human gene map, because of them starting 
so early. Later it exploded, but at the time there were like 150 probes or 200 
probes that showed a polymorphism, while now it’s billions. So this was really 
a field where the sharing was extremely important and Peter Pearson was really 
adamant. I came from a molecular biology lab that was much more restrictive 
studying a specific field, and here you had this boss who said that as soon as you 
45 Lothe et al. (1986).
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had something that was of any utility, ‘buy 20 Jiffy envelopes and fill 20 tubes 
and just send it around to all your, well, colleagues but also competitors.’ That 
was sort of a mental transition.
Bakker:  Maybe a little to add to that: by sharing these probes, we had this 
switch to Duchenne, but in 1981 the request for these probes was so high 
that we organized a meeting in Leiden. So Peter Pearson and I, and from the 
States, Ray White,46 Web Cavenee,47 David Barker,48 and Mark Skolnick,49 all 
co-organized this meeting in Leiden where we had clinical geneticists and 
people from laboratories in Europe on this course, a two-week course, where we 
demonstrated the cloning in plasmids, the Southern blotting, and showed how 
they worked.50 For these two weeks we had this course and all these clinicians 
went home with probes that they had made themselves. So we were, at that 
time, starting to get more of these and, of course, we gave our probes so they 
could use them in Southern blotting and show that worked in their lab.
Temple:  So, how did ‘we’ find the gene for Duchenne?
Bakker:  With linkage, the gene was there. The gene was already mapped by 
using the girls with the translocation. The gene was located in the middle of 
Xp21, so in the middle of the short arm, but getting the probes closer you got 
linkage with the gene, with the defect in the families, and getting closer and 
closer, at a certain point we came at the position where we had probes on either 
side of the gene. But it was the same probe. In one family it was under the gene, 
and in the other family it was above the gene, so we couldn’t localize the gene. 
Later, Gert-Jan van Ommen, using pulsed-field gel electrophoresis, showed that 
46 Professor Raymond White is Rudi Schmid Distinguished Professor in Neurology at the University of 
California, San Francisco; see http://humangenetics.ucsf.edu/white-raymond/ (accessed 11 January 2017).
47 Professor Webster K Cavenee is Director of Strategic Alliances in Central Nervous System Cancers at 
the Ludwig Institute for Cancer Research; see www.ludwigcancerresearch.org/bio/webster-cavenee-phd 
(accessed 11 January 2017).
48 Dr David F Barker is a lab research manager at the University of Louisville; see http://louisville.edu/
directory/index.php?record=2&query=david%20barker (accessed 11 January 2017).
49 Dr Mark Skolnick is the founder of Myriad Genetics, Inc.; see www.dnalc.org/view/15718-Mark-
Skolnick.html (accessed 11 January 2017).
50 The postgraduate course was entitled Restriction Fragment Length Polymorphisms and Human Genetics 
and took place at the University of Leiden (19–30 July 1982). For more details, see Jones and Tansey 
(2014), page 11.
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the gene was actually much larger than we ever thought.51 It was two Mb long,52 
so it was a huge gene. So sometimes the disease defect was on one side of the 
gene and the probe was on the other, and sometimes it was vice versa.
Temple:  And the Kunkel lab,53 how were they involved?
Bakker:  They cloned the gene.
Temple:  They cloned it. What difference did that make to your…?
Bakker:  Actually, one of the probes, 754, of which I talked before, was located 
in a deletion found by Uta Francke’s group,54 and this deletion on the X 
chromosome was a very tiny deletion on chromosome X [Xp21], but you could 
almost see it. Uta Francke said: ‘There is a deletion’, and this probe, 754, fitted 
exactly in this deletion. It was close to the Duchenne gene because this boy with 
the deletion had Duchenne muscular dystrophy. Later it turned out he also had 
chronic granulomatous disease, McLeod syndrome, and retinitis pigmentosa.55 
A set of genes were missing there, and also the Duchenne was hit. And this 
probe was very close. Then in the group of Lou Kunkel, Tony Monaco used 
this patient with the deletion, this BB deletion patient,56 used that DNA to 
clone the DNA that was missing.57 So he cloned actually the deletion by putting 
an overdose of normal X chromosome DNA (from a 49, XXXXY patient) to 
hybridize with this deletion DNA and pull it (the missing DNA) out; the BB-
deletion DNA was sheared and the other was digested, and he could take out 
51 van Ommen and Verkerk (1986).
52 The equivalent of 2,000 kb.
53 Professor Louis M Kunkel is Director of the Program in Genomics at Children’s Hospital Boston, and 
Professor of Genetics and Pediatrics at the Harvard Medical School, Boston; see www.childrenshospital.org/
researchers/louis-kunkel (accessed 11 January 2017).
54 Professor Uta Francke is Professor of Genetics and Pediatrics Emerita at Stanford University; see https://
med.stanford.edu/profiles/uta-francke (accessed 11 January 2017).
55 Francke et al. (1985).
56 The letters ‘BB’ refer to the patient’s initials.
57 Professor Anthony (Tony) Monaco was a PhD student in Kunkel’s lab, and is now President of Tufts 
University; see http://president.tufts.edu/biography/ (accessed 11 January 2017). See, also, Kunkel et al. 
(1985) and Monaco et al. (1985). Professor Gert-Jan van Ommen commented: ‘Tony came later, the 
deletion cloning really was Lou’s work.’ Note on draft transcript, 2 February 2016. For a useful resource on 
the discovery of the Duchenne muscular dystrophy gene, see Kunkel (2005).
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the probes, and reach for the probes in that region. And some of the probes 
really showed also deletion in Duchenne patients. And then he was close, he was 
in the complementary DNA (cDNA), he could find the cDNA.58
van Ommen:  Just one anecdote from 1984. In the spring of 1984, the whole 
of the Duchenne community was organized at a meeting by the Lions Club in 
the Netherlands and all the people, Ron Worton59 and Uta Francke and Kay 
Davies, essentially everybody was there. That was at the time when we had 
these 754 and 782 probes, and we felt that it was very close. Peter had heard 
that Uta Francke had this patient with a deletion so he actually, at that meeting, 
talked Uta into testing that patient. Then the news came back, still in the early 
summer of 1984 and not yet known to others, that this 754 probe was absent 
from that patient. That was the summer when I went on holiday to the United 
States and I visited some of the people there, because I worked only for a year 
in Peter’s lab. I first visited Ron Worton, then visited Kunkel’s lab, and then Uta 
Francke at Yale. And then, we knew at the time but we hadn’t written it up yet, 
that this probe was mapping in the BB deletion. But what we didn’t know was 
that Lou also had the BB DNA. The person who originally discovered this BB 
deletion, a paediatrician in the West Coast of the United States, Hans Ochs,60 
didn’t really want to part with his deletion, because Uta was still studying it. But 
Lou Kunkel’s boss, Sam Latt is, or was – he died later – a bit of an overpowering 
person,61 and he wrote to Hans Ochs himself that he had to send this DNA or he 
would, well, come in action to get it, because this wasn’t fair. And so the Boston 
lab also had this deletion. And Lou, but we didn’t know that at the time, already 
had the first probes that were isolated using this trick of getting the probes out 
of the deletion. So I came in this laboratory, I was sat down in the library, and 
when Sam Latt came in I had already told Lou that we had 754 that mapped 
in the deletion. I’ll never forget how Lou turned around and said immediately 
when Sam entered: ‘Sam, they have a probe in the BB deletion’ and Sam, a big 
man, he just sort of deflated and said: ‘That is most unfortunate.’ [Laughter]. ‘I 
mean, congratulations.’ But even then we weren’t told about Lou’s own probes, 
so I went visiting Uta Francke, none the wiser. Only later, in the fall of 1984, 
58 Monaco et al. (1986).
59 For Professor Ronald Worton, see www.ohri.ca/profiles/rworton.asp (accessed 11 January 2017).
60 Professor Hans Ochs is Professor of Pediatrics and Immunology at the University of Washington; see 
https://depts.washington.edu/chdd/iddrc/res_aff/ochs.html (accessed 11 January 2017). See, also, Francke 
et al. (1985).
61 For more details on Samuel (Sam) Latt (1938–1988), see his obituary: Willard (1989).
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there was a meeting in Oxford, led by, I think, David Latchman.62 Lou Kunkel 
was invited, and Kay spoke, and I spoke, and a lot more people spoke, and 
then Lou presented his strategy of this phenol-emulsion reassociation technique 
(PERT)63 and he had a very nice model of how it would work.64 So that was 
actually when it came out that he had those probes, seven different probes that 
all came out of that deletion, and that he was testing them and that some probes 
actually detected deletions that were never found before. 
Professor Eric Hoffman:  I think you went over linkage, it was mentioned 
very nicely and eloquently. The linkage data really went, later, directly to the 
identification of disease genes because you could narrow it to a very fine interval. 
But, as was commented, you ended up with these enigmatic results in Duchenne 
specifically where, as was mentioned by Bert Bakker, you ended up on one side 
or the other of your probe, and in terms of linkage that really didn’t make any 
sense and so the linkage only got you so far. So, just to summarize what Gert-
Jan said, you then needed a physical map. You needed to figure out where these 
different probes and deletions were, and that’s what was just summarized; so 
62 Professor David Latchman is the Master of Birkbeck College, University of London; see www.bbk.ac.uk/
about-us/governance/officers/master (accessed 11 January 2017).
63 Kunkel et al. (1985).
64 Professor Gert-Jan van Ommen commented: ‘And then he surprised everyone by showing that it had 
worked exactly as planned.’ Note on draft transcript, 2 February 2016.
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there were more and more people with more and more probes and deletions 
and it looked like it was covering a big area. Well, the next step really was to 
identify the gene itself, and that really became challenging, because you have a 
lot of intron and not much exon and, in fact, this gene – just by chance – has a 
much greater proportion of intron than exon. So there are about 200 base pairs 
of intron to every base pair of exon. So you’re sort of put into the desert saying: 
‘Okay, find the oasis,’ and all you see is sand everywhere, wondering which 
direction you should walk in. That was really the challenging part and sort of 
hit the wall as far as the field was concerned. There were different attempts at 
different areas of the gene to try and find that oasis, really by walking; it was 
called ‘chromosome walking’, one direction or the other.
Ron Worton’s group was walking in one area, and Gert-Jan’s was walking in 
another area, so you’re all in different parts of the Sahara looking for an oasis. 
There’s more than one exon, and it turned out there were a lot of exons, but 
they were really spread out and really small. They were on an average of 100–
200 base pairs, where your introns could be 40,000 or 400,000; some of the 
introns were enormous. So it just happened that Lou Kunkel’s lab ended up in 
the area of the desert with quite a few oases, whereas Ron Worton unfortunately 
was looking for one oasis really far away. That was very much a chance thing at 
that point. So how was that first exon discovered, which really is ‘the gene’ when 
you get a handle on the RNA as opposed to just oceans, or deserts of introns, is 
through what we call ‘zoo blots’. You look to see which part of the DNA would 
cross-hybridize to the animals from the Smithsonian Zoo in Washington DC. 
So there was one around the PERT 87 walk that then would cross-hybridize, 
and then the couple that then became, because they were more highly conserved 
as exons, instead of introns being poorly conserved, gave you at least a hint 
that this might be an exon. The next step if it is an exon, it should show up in 
an RNA and then you’re starting into these RNA libraries or cDNA libraries, 
which are relatively new at that time. And one of the problems was that it was 
starting to look like this might not be a normal gene, or a normal RNA or a 
normal protein.
Temple:  In what context? This was one of the first genes ever to be cloned, is 
that right?
Hoffman:  Well, there were other genes that were cloned, like haemoglobin and 
others, but the distinction really is that in all those other diseases you had some 
hint as to the biochemical defect first. Then you either used the protein to 
get at the gene, or had hints about what the protein dysfunction was. Why 
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this is called ‘the first positionally cloned gene’ is that you had no hints about 
the protein or biochemical abnormality and you really had to start from the 
code itself in order to try and dissect backwards – it was at one time called 
‘reverse genetics’; that lost favour. But ‘positional cloning’ just by positioning 
the gene. The difference is – again, to make that distinction – that in most 
other positionally cloned genes, the linkage was the be all and end all, whereas 
in this gene, the linkage only got you so far and you sort of hit a brick wall, 
and that brick wall ended up being this effort to find these tiny exons in these 
seas of introns, or deserts of introns. So one of those then ended up in cDNA, 
and so that’s when I came to the lab to help clone what ended up being a very 
large RNA, so 14,000 base pairs. We estimated at 16,000.65 With the RNA 
and cDNA in hand you could then sequence everything and decode it, and 
that became the ‘dystrophin’ protein, and you can make antibodies against the 
predicted sequence.66 
Temple:  And how quickly did you share that with everyone?
Hoffman:  Very, very quickly, often before publication. And even, for example, 
the first piece of cDNA was published with its amino acid translation way ahead 
of the whole thing being known, which meant that anybody could then make 
peptides and make peptide antibodies against that sequence. And everybody 
did. So then you could make the probes to then clone the cDNA as well. But 
Anthony Monaco was an MD/PhD student who did a phenomenal amount of 
work in as far as particularly he had cloned so much real estate.67 He had a lot of 
the map of the desert, and knew where different oases were and where different 
mutations were breaking and those different exons. So there ended up being a 
lot of resources that were able to be brought to bear to find these initial exons, 
find the cDNA, and then convert that into the protein and antibodies. 
Temple:  Was it difficult to get funding for Duchenne muscular dystrophy from 
funding bodies?
Hoffman:  I think it’s generally always hard to get funding for anything [laughs]. 
That’s the nature of research but there was a lot of enthusiasm at the time 
and there was a lot of focus on this disease. So I think maybe, as a group, we 
were more successful than many others. The other thing was you had great 
65 Koenig et al. (1987).
66 Hoffman, Brown, and Kunkel (1987).
67 For more details on Anthony Monaco, see note 57.
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foundations behind the effort, like the Muscular Dystrophy Association of 
America (MDA) and others.68 So I don’t remember, at the time, money being 
limiting but, you know, those were generally good days.
Dubowitz:  If I recall, the MDA offered a million dollars to somebody who 
discovered the gene, or cloned the gene, and I think the British followed on with a 
million pounds or something equivalent, and I think that’s in a sense how individual 
people – certainly Williamson, I think – were attracted [laughter] by that.69 
van Ommen:  One thing, intermediate between that, was the mapping stage, 
because at the same time this was a gene, but it was also almost a genome. 
It had deletion hot spots and deletion cold spots and it spanned forever and 
ever and ever. So one of the technologies in those days was developed by the 
genomic community during the early days: the group of Charlie Cantor and 
other people had these pulsed-field gels where you could resolve pieces of DNA, 
of say one million base pairs or half a million base pairs, and map them on top 
of, or just relative to, each other.70 So by the time that all these bits and pieces 
came out of the Duchenne gene, it got to be very attractive to actually make 
a long-range map of it. That was also around 1986, our group made a map,71 
Margit Burmeister in Hans Lehrach’s group in Heidelberg also made a map,72 
and later Sue Forrest in Kay Davies’ group, too.73 
Well, not to anybody’s amazement, the maps were pretty consistent and then, 
the next game was actually jumping across the deletions of patients. Lou Kunkel 
gave everybody all the probes, but there was one condition: they could do what 
68 The Muscular Dystrophy Association (MDA; originally, Muscular Dystrophy Association of America) is 
a non-profit organization and major funder of research on muscular dystrophy; see the charity’s history at: 
www.mda.org/about-mda/history (accessed 11 January 2017).
69 For more details on Bob Williamson, see note 17. 
70 Professor Charles R Cantor (b. 1942) is Professor Emeritus of Biomedical Engineering and Professor 
of Pharmacology at Boston University; see www.bu.edu/bme/people/emeritus-faculty/cantor/ (accessed 11 
January 2017). For more details on the pulsed-field gel electrophoresis technique, see Schwartz and Cantor 
(1984) and van Ommen and Verkerk (1986). 
71 van Ommen et al. (1986). 
72 Burmeister and Lehrach (1986).
73 See, for example, Paulsen et al. (1986). Professor Gert-Jan van Ommen commented: ‘The Human 
Genetics paper was just a map of the X chromosome of probes. Many groups had that. What I meant was 
around the Duchenne muscular dystrophy gene. I remember a paper with Sue Forrest as first author, in 
1987, most likely: Forrest et al. (1987).’ E-mail to Dr Apostolos Zarros, 24 January 2017.
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they wanted and map the deletions, but they would provide the data to Lou 
to publish jointly. That was a paper, one of the very early multi-author papers. 
Kunkel et al. had 75 authors or so, a Nature paper.74 All the different deletions 
were then used to just jump from the one end of a deletion to the other end 
of the same deletion, to actually sort of saturate the map. Most fit on the 
map that I made, but there was one patient in the Leiden contingency, DL66, 
and we made this jump from that patient, J66, and it turned out that this 
jump was essentially a jump across a gap of 1.2 million base pairs. We already 
knew that there was a sizeable portion of the gene before this 1.2 million base 
pairs, but then we jumped into a place where there was another Duchenne 
family with a deletion that actually began yet distal of that specific position. 
That essentially clinched the deal that the whole thing had to be more than 2 
million base pairs. It was in the fall of 1987 or so that it came out that this was 
really so huge, and that was just by jumping around using actually the patients’ 
deletions to get it.75 
If you look for history filling in, there was one thing that we glossed over: in 
the earlier days there was heavy opposition by Peter Harper for one of the 
closest probes, this 754 probe, that it should be so close because he said: ‘This 
can’t be because this probe has 20 per cent recombination in our families. 
That’s about 20 million base pairs away.’76 So we still had this puzzle because 
in everybody else’s, it showed 3 per cent recombination and that’s sort of an 
unbridgeable inconsistency. The answer came at the time that we found all 
those probes detecting small deletions in patients, because, then, the nature 
of diagnosis also changed. It was no longer RFLP diagnosis, as now in 60 per 
cent of the cases you could actually detect deletions from the pieces that you 
had from the gene. That meant that you could actually see deletions happening 
in mothers that had de novo deletions. I think that one of the real discoveries 
that Bert made was the germinal mosaicism situation, where you found that 
one mother, without having any rearranged X chromosome herself, could 
actually give the same deletion to two subsequent sons having her same X 
chromosome.77 Later, it turned out that this happened quite often when you 
74 Kunkel et al. (1986).
75 van Ommen et al. (1987).
76 Harper et al. (1985).
77 Bakker et al. (1987).
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had new mutations in any chromosome, but in those days it was totally new 
and really complicated the diagnosis. There was even a case in a family from 
Christine Van Broeckhoven,78 which seemed a clear new mutation family, but 
right when the germline mosaicism came about, and Bert said: ‘Well, you 
know, you just never know. Do a prenatal diagnosis, you never know. Let’s 
have a look.’ And indeed, the same deletion!
That, two years later, retrospectively explained Peter Harper’s situation because 
he had a mother with two Duchenne patients.79 But then they could only use 
linkage so they couldn’t follow any deletions. So it seemed as if there were two 
recombinants in one family and then you get to 20 per cent recombination.80 So 
it was by the time you could actually discover all these gaps that suddenly this 
weird behaviour genetically became clear. 
Sturdy:  The story I’m picking up on is the enormous complexity of the gene 
and the multiplicity of possible abnormalities that there could be in the gene. I 
guess the story that I’m used to, as a historian, is that you discover what’s wrong 
with the gene, you come up with a diagnostic test and then you can use that 
diagnostic test. But it sounds as though there are so many things you could be 
looking for here, that the way this impacts on diagnosis is going to be hugely 
complicated and the relationship between diagnosis and investigation research 
seems to be a very blurry one in this case.
van Ommen:  It still goes on. We’re trying to describe a room without the light on. 
Using a torch light we have some idea of the room, and then somebody flicks on 
the switch and you see that it looks very different to how you thought. In a way 
I sometimes compare it with particle physics and the waves, in that the waves 
only go so far to explain matters and then your resolution becomes so precise 
that you can no longer describe the thing in your classical concept, and there 
is a new concept. But, of course, the new concept, when you make everything 
78 Professor Christine Van Broeckhoven is Director of the Department of Molecular Genetics at the 
University of Antwerp; see www.vib.be/en/research/scientists/Pages/Christine-van-broeckhoven-Lab.aspx 
(accessed 11 January 2017).
79 Bakker et al. (1989). Professor Gert-Jan van Ommen added: ‘and the 754 allele tracking a proven healthy 
X elsewhere in the family tracked the Duchenne X in her two sons.’ Note on draft transcript, 2 February 
2016.
80 Professor Gert-Jan van Ommen added: ‘In reality, the X chromosome with this previously “healthy allele” 
had undergone a deletion in a percentage of her oocytes, ending up in two sons.’ Note on draft transcript, 
2 February 2016.
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approach infinite in that scale, must fit in the old classical theory. And that’s 
the same with genetics in that when we had single-nucleotide polymorphisms 
(SNPs) every million base pairs, we could speak about the Hardy–Weinberg 
equilibrium.81 Nowadays with the 100,000 Genomes Project,82 people being 
sequenced all over the place, the Hardy–Weinberg equilibrium turns out to be 
simply non-existent. Nobody thinks of people mating at random in populations. 
So that’s the same thing.
Temple:  Are there other memories about that time of using the gene?
Professor Kate Bushby:  I started in genetics in 1989 and my first project was 
on muscular dystrophy so, of course, I was launched into exactly this whole 
environment. Newcastle had played a large role in contributing families to the 
big effort for identifying the gene, so Angus Clarke had spent, I think, his 
81 Hardy–Weinberg equilibrium suggests that in a very large random-mating population, the allele and 
genotype frequencies will remain constant from generation to generation, provided that other evolutionary 
influences are not present. It was developed in 1908 independently by the British mathematician Godfrey 
Hardy (1877–1947) and the German physician Wilhelm Weinberg (1862–1937). For more details, see 
Stern (1943).
82 The 100,000 Genomes Project is a British project launched in late 2012 and aiming to sequence 100,000 
whole genomes of National Health Service (NHS) patients. It is led by Genomics England, which is owned 
by the UK Department of Health; www.genomicsengland.co.uk/the-100000-genomes-project/ (accessed 
11 January 2017).
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The Therapeutic Implications of Muscular Dystrophy Genomics
28
research time in Newcastle collecting up all of the families.83 So I inherited 
these fantastic sets of notes – often patients who had originally been seen by 
John Walton,84 who were still being followed up by David Gardner-Medwin,85 
where Angus had taken the families, had gone out into the coal mining villages 
in County Durham, and had met all these mothers who had had children with 
Duchenne who had died, and from previous generations, and there were still 
quite a number of big, big families with surviving children and people who 
had died. Of course, this was also mixed in with the Becker population, so 
we had very large Becker families as well.86 The other context with that was, 
I think, by that point Louise Anderson, then Louise Nicholson,87 had gone 
to visit you, Eric [Hoffman], in your lab to start making the antibodies that 
became the diagnostic antibodies in use in many labs – Novocastra antibodies 
for dystrophin – which are still in widespread use.88 So our diagnostic paradigm 
was very much based around the muscle biopsy, because Louise had made these 
antibodies and so we were revisiting all of our old muscle biopsies, looking at 
the dystrophin, trying to tell whether there was dystrophin present or absent, to 
try to distinguish between Duchenne and Becker. Then we had the paradigm, 
which is clearly the other way round to what we do now, of trying to get the 
genetics confirmed. My experience of that early NHS translation of these 
findings – and I’m sure it was your experience as well – was that it was really 
difficult to get the results.
83 Professor Angus Clarke is Clinical Professor at the University of Cardiff. He spent a few years at the 
University of Newcastle and, there, he developed the Duchenne register; for more details, see his oral 
history interview by Peter Harper, available at https://genmedhist.eshg.org/fileadmin/content/website-
layout/interviewees-attachments/angus-clarke-interview.pdf (accessed 11 January 2017). See also Reynolds 
and Tansey (eds) (2010) and Jones and Tansey (eds) (2016).
84 John Walton, Baron Walton of Detchant (1922–2016) was Professor of Neurology and Dean of 
Medicine at Newcastle University. He served as President of the British Medical Association (1980–1982), 
President of the General Medical Council (1982–1989), and President of the Royal Society of Medicine 
(1984–1986). He was also a founder of the Muscular Dystrophy Group (now Muscular Dystrophy UK) 
and its Honorary Life President; see Meadowcroft (2015).
85 Dr David Gardner-Medwin (1936–2014) was a paediatric neurologist, a colleague of John Walton and 
an expert in muscular dystrophy; see Gulland (2014).
86 Becker muscular dystrophy is a type of muscular dystrophy that refers to a group of genetic, degenerative 
diseases primarily affecting voluntary muscles.
87 Nicholson et al. (1989a and b). 
88 Novocastra antibodies were sold by Novocastra Laboratories Ltd (founded in 1989 and based in 
Newcastle upon Tyne). The company is currently known as Leica Biosystems Newcastle Ltd.
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Temple:  It was all the maths.
Bushby:  Well, there was an awful lot of maths; there was an awful lot of working 
out of risks of carrier status based on linkage and so forth, and CK, and building 
it all into your analysis. But it was also a case of our lab really struggling at a 
diagnostic level to produce good Southern blots, so you’d get a result maybe six 
months later of one probe, which, of course, just gives you a very partial picture 
of what’s going on. We worked very closely with the Leiden group. I remember 
Louise just deciding to package up all the DNA samples and send them to Bert 
[Bakker], because that was a much better way to get a result than to try and 
wait for the NHS diagnostic service to produce any results. That was when 
we worked on the 70 or 80 families that Angus [Clarke] had put together to 
correlate the clinical findings with the DNA, and, of course, Louise’s results on 
her dystrophin quantification, which she was very, very good at.
Temple:  That’s really interesting. Have other people got memories of that time 
using the probes in clinical practice?
Bakker:  Of course, these families had a lot of profit from this new diagnostic 
work because, before that, they were relying on CK analysis for carrier detection. 
And, as shown in the old papers of Sarah Bundey on CK analysis for carriers, 
that was sometimes a disaster.89 So you couldn’t rely on that. So most of the 
families were told that it would be better not to have children or to have no 
sons, and if they did a prenatal diagnosis, to terminate all boys, even the healthy 
ones. Now with DNA markers you could discriminate between an affected and 
a non-affected boy. So from 1985 on, we could do prenatal diagnosis and, for all 
the families that we had collected by then, we were doing the carrier detection 
and prenatal diagnosis. So the diagnostic part started quite early on.
Professor Shirley Hodgson:  I worked a lot with Victor Dubowitz at the 
Hammersmith, and we saw many hundreds of patients, because, of course, 
Victor accumulated them over many years. I remember being very involved 
with using these molecular probes in order to refine the carrier risk for these 
women, mothers of boys with Duchenne muscular dystrophy. It was so helpful 
because I remember it was so agonizing initially when they would just say 
they would terminate all male pregnancies, and they knew that at least half 
of these would be fine. So, although the linkage didn’t give them an absolute 
guarantee that they were or weren’t a carrier, pretty much 90 per cent of the 
time we could give them some alteration of their risk, and quite often this was 
89 Bundey (1978).
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sufficiently small to allow them to take a very small risk. I remember also when 
assessing risk, I might find myself giving a certain risk and they’d say: ‘Ooh, 
but you mean that’s one in three?’ or whatever it was. The sorts of risks that 
people were willing to take in a pregnancy seemed to be about 5 per cent or 
below that the child would be affected, because, clearly, having had a son with 
this terrible disorder you just couldn’t face it happening again. I remember 
going into the clinic before I knew the diagnosis sometimes, and you could 
tell by looking at the mother’s face whether she had a child with Duchenne or 
with some other problem. 
Bushby:  I remember one family, it was a sister of a boy with Duchenne, 
who’d had a couple of terminations of male pregnancies before the testing was 
available, and then we moved into being able to use the probes for linkage and 
so on. We couldn’t define the mutation – it turned out it wasn’t a deletion – so 
it was very difficult because, of course, point mutation detection didn’t come 
until later, and we worked with this family to try and define the linkages and so 
forth. In the end, what we did was we took the at-risk chromosome and then 
tested the at-risk chromosome and she decided to have a termination based on 
this being present in a male fetus. Then we used the dystrophin testing from the 
terminated fetus to show that she wasn’t a carrier. It was so bittersweet, because 
she’d already by that stage had so many terminations and she did subsequently 
go on to have a couple of children who were unaffected, but it was years and 
Figure 9: Professor Shirley Hodgson
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years of testing and her unwillingness to take any degree of risk. Just as Shirley 
said, you went down to a tiny risk really, but even at that point, she was unable 
to take any risk at all.
Temple:  I was also practising, and I started off as a Duchenne Muscular Dystrophy 
Fellow in about 1987. One of the things I remember is the responsibility of 
using your wonderful probes, but coming out with risks like 12.25 per cent that 
the patient was at risk. I was really worried about using the prior probabilities 
and trying to get this right, let alone explaining what the risk was that I was 
giving to patients and what people thought it meant, because it really was quite 
complicated. Professor Robin Winter90 would come and visit the Department 
at Great Ormond Street because he was really good at maths, and so I refused 
to give any of these results until I’d sat down with him and we’d gone through 
all the results and I got really good at doing Bayesian calculation.91 But, on the 
other hand, it was a very unusual time and it was such a relief when we started 
to be able to detect those actual deletions and you could say: ‘Yes, this boy really 
has got the deletion’, and even more when you could tell whether a woman was, 
in fact, a carrier. But by that stage, I’d moved into more general clinical genetics, 
because that was really the early 1990s. Are there other memories of that time?
Hodgson:  I remember how exciting it was when people started finding the 
deletions in the Duchenne gene in these boys, but it was such a long time 
during which we didn’t know why different deletions caused different degrees 
of severity of disease, and there were so many Becker boys who had deletions 
and also those with Duchenne that had deletions, and sometimes the Duchenne 
deletion was smaller. I remember we had this big chart on the wall of all the 
different deletions, and I was looking at it saying: ‘There must be some reason 
why some deletions give rise to Duchenne type muscular dystrophy and others 
give rise to Becker.’ It was a long time before we realized the reason why.
Temple:  Does anyone remember how that came about?
van Ommen:  There was a meeting in April 1987 in Versailles where Tony 
Monaco presented the story, or at least his model, that depending on the specific 
frame consequences of the loss of the exons, you would either make an in-frame 
90 Professor Robin Winter (1950–2004) was a consultant clinical geneticist who worked at the Great 
Ormond Street Hospital for Children and became Professor of Dysmorphology and Clinical Genetics in 
1994; for more details, see Donnai (2004).
91 For more details of Bayesian analysis and its application in genetic counselling, see Ogino and Wilson 
(2004).
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or out-of-frame deletion.92 So he presented that there. That was actually also the 
meeting where the germline mosaicism was presented by Bert and picked up by 
Marcus Pembrey.93
Temple:  But it took a bit of time to get into clinical practice, because we didn’t 
really necessarily know that was true at that time.
van Ommen:  Well yes, I know, sometimes these things take time. But still, 
if you talk about the timing, I think that was the moment. Then there were 
two papers that actually looked at the consequences of all the deletions on the 
reading frame. There was one, if I’m not mistaken, by Michel Koenig from 
Kunkel’s lab and one by Beth Gillard.94 But there were also people who said, 
‘It doesn’t always fit.’ And then it turned out why it didn’t always fit: that was 
that sometimes deletions would creep up so close to a specific exon that the 
splicing of that exon didn’t go right anymore. So that the deletion at the RNA 
level – and that’s, of course, what makes the protein – looked different from the 
deletion at the DNA level. At the DNA level it looked like being out-of-frame, 
while because there was an extra exon missing in the messenger RNA, it would 
be moved back into frame so that most of the exceptions to the reading frame 
rule, ultimately, were explainable when you looked not at the DNA level, but 
when you looked at the RNA level. 
Hoffman:  I think a key part of that was that the proteins were going in parallel 
with gene data, where we could show that Becker was due to a partial loss 
of function with those whose dystrophin was present but abnormal, whereas 
Duchenne was generally a loss of dystrophin. And that would correlate so well 
with the molecular defects, except for the exceptions you just mentioned; it 
made sense in the end.95
Professor Francesco Muntoni:  I’m too young to be able to contribute a lot 
to this early part of the events, although I did spend a little time during my 
paediatric neurology training in London with Victor [Dubowitz]. Then, I 
went back to Italy for several years, so I was involved in developing very similar 
techniques to what Kate [Bushby] had been involved in using. Unfortunately, 
92 Monaco et al. (1988).
93 For a recent interview with Professor Marcus Pembrey, see http://dx.doi.org/10.17636/01012627 
(accessed 11 January 2017).
94 Gillard et al. (1989) and Koenig et al. (1989).
95 Hoffman et al. (1989) and Kunkel, Beggs, and Hoffman (1989).
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prenatal diagnosis was very complicated in unaffected males. In those days, 
people did not store DNA of somebody who had died, so I think the only 
source of DNA was unfortunately, in many families, the fetus. I started to 
become more involved with the protein part, and I think I was following work 
done by many people in order to understand a little more about the exception 
to the rule, because the genetic prediction is true in approximately 89 per cent 
of the cases, and 89 is not 99. This is true in both directions, meaning you 
can have in-frame mutations that are still severe if you’re missing some crucial 
part of the molecule, and that observation helped indirectly to identify the 
functional strong domain of dystrophin.96 I’m not saying this is all my work; 
this is work done by many other people. And vice versa, there are the mutations 
that should theoretically not allow the production of any protein, but that, 
unexpectedly, are associated with a much milder phenotype. So I did some of 
the work at that time.97 
I go back to the original question; when I think we started, the first question 
was: what is special about this condition? What, from a diagnostic perspective, 
makes you think about Duchenne? This makes me think about the central 
96 See, for example, Gilgenkrantz et al. (1989), Malhotra et al. (1988), and Nicholson et al. (1990).
97 Muntoni et al. (1993, 1994).
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nervous system manifestation of the condition. You will understand why I’m 
saying this because, I think, apart from the skeletal muscle problem, which 
these children have, the specific neuropsychological profile of 50 per cent of 
these children, and the mental retardation present in one third of these children, 
give you a good strong clue about the Duchenne muscular dystrophy diagnosis 
if those are present. If you’re dealing with a child in whom those are not present 
at all, then, of course, the differential diagnosis with other conditions, muscular 
dystrophy and so on, is challenging clinically. Well, very challenging with some 
other rare forms of muscular dystrophy. However, once you have a child who 
fits the full neurobehavioural profile of Duchenne muscular dystrophy, then I 
think you are left with a much smaller differential diagnosis. Coming back to 
why I am saying this, firstly for the clinical perspective, but secondly, because 
I was interested. I come from a paediatric neurology background and my MD 
was on neuroscience, on aspects of dystrophin in the brain using, for example, 
dystrophic mice as a model to test whether their behaviour was normal or 
not.98 And actually you could identify some subtle differences, so I think a very 
interesting part that went in parallel to the work that was done to identify what 
is dystrophin, what is the function of dystrophin in skeletal and cardiac muscles. 
But then, the very interesting aftermath of multiple, shorter isoforms, each 
with their promoters, have been discovered one after the other. And then, little 
by little, that falling into place in terms of correlation between genotype and 
phenotype, also for the cognitive problems in people with Duchenne muscular 
dystrophy; that, I think, now we understand reasonably well, not 100 per cent. 
But 10 years ago, we didn’t really understand that very well at all.
Temple:  Was the cognitive phenotype well recognized before you could diagnose 
Duchenne so accurately?
Muntoni:  Yes, I think it was already known. Victor will remember better than 
me. I think this was probably already in the description from Duchenne.99 In 
the very original description there was realization that many of these children 
had more than just muscle weakness. At that time it wasn’t clear whether this 
was really related to, if you like, the biological basis of the disease or whether 
this was related to the fact that they were neglected.
Temple:  Never had schooling?
98 Muntoni, Mateddu, and Serra (1991).
99 For more details, see Emery and Emery (2011).
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Muntoni:  Not exposed to normal life, and then a number of papers came 
suggesting actually it’s nothing to do with how weak these people are because 
if you take disease control – for example, spinal muscular atrophy where there 
is a similar level of difficulties in integrating in life – they have entirely normal 
cognitive behaviour, so it must be something true about Duchenne. It was then 
the discovery of the shorter isoforms and the early localization – and now still 
presume function – that allow to help, to close that circle. 
Dubowitz:  In the 1950s and 1960s there was a big argument going on: a lot of 
people said there’s no mental retardation, it’s simply lack of opportunity and all 
this. But then, as Francesco mentioned, the contrast with spinal atrophy patients, 
who were much more disabled but fairly bright – in fact, they had above average 
type of intelligence – showed that it wasn’t that. I studied a group of about 65 
Duchenne’s in the mid-1960s, and all of them had a psychometric assessment on 
the usual Wechsler Scale type things;100 and what was very interesting, one got a 
Gaussian distribution with a shift to the left of about one standard deviation.101 
So the medium came out somewhere around 85. And it’s interesting that a lot of 
subsequent studies have always shown more or less the same type of distribution. 
So I think you’ve got the very bright ones, you’ve got the obviously below average 
within the retardation group, and then you’ve got a sort of scatter across, so there 
is a consistent sort of element. Then, I think Shirley did some early studies trying 
to link the retardation part with particular mutations or whatever in the gene, 
but that’s still going on, I think, to an extent.102
Temple:  It’s too difficult. And the phenotype in carriers, the parents of, or the 
mothers of these boys? When was it appreciated that there was a real phenotype 
in carriers? Was that always known?
Dubowitz:  The phenotype, you mean the clinical phenotype?
Temple:  The clinical phenotype, yes, in carrier women. 
Dubowitz:  In 1963, Alan Emery and I wrote independently separate case reports 
at the time,103 and we both observed something similar and that was a mother 
with enlarged calves and looking slightly abnormal, although with no obvious 
100 The Wechsler Intelligence Scale for Children is an individually administered intelligence test for children 
between the ages of 6 and 16.
101 Dubowitz (1965).
102 Hodgson et al. (1992).
103 Dubowitz (1963) and Emery (1963).
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clinical weakness. We did biopsies at the time, which showed some pathological 
change. And so this would relate, of course, to CK sometimes being very high 
as well. So you can actually pick up a certain amount of pathology in some 
of the carriers, because there was a lot of contention still at that time whether 
carriers actually have got any manifestation. But, certainly, about 10 per cent 
were thought to have actual clinical weakness.
Temple:  In the early 1990s, late 1980s, we didn’t really worry about the mothers 
particularly. I don’t know when that came in.
Hoffman:  I think that the key thing with the carriers was some of the early 
cases of X chromosome translocations in girls that had severe Duchenne 
actually were one of the first ‘events’ that led us to map the gene to Xp21. 
And in those it’s often a quite severe phenotype that you often didn’t see just 
in typical characters, and you had a cytogenetic or molecular explanation at 
that point, because of what’s called ‘skewed exon activation’, that the girls 
– because of dosage abnormalities – had to keep the translocated X active, 
which meant they preferentially shut down the normal X. Now ‘preferentially 
shut down’ really meant that those cells at the point of exon activation – at 
about the 100 cell stage in embryogenesis, where both Xs are active and cells 
should randomly decide which X is inactivated – those with the normal X 
active had a dosage problem. And so they then had to keep the translocated 
X active, because they were shutting down some autosome and didn’t have 
the right number of X chromosomes, and it has to do with Xq13 and the X 
inactivation centre. So those cells had a growth disadvantage, and as a result 
you ended up with these X autosome translocation girls with clearly skewed X 
inactivation. You had a molecular and cellular mechanism for it that all made 
sense, and that led then to searches for ‘skewed inactivation’ that weren’t due 
to translocations.
Temple:  And that started in Duchenne?
Hoffman:  Well, I think there are a number of examples in other genetic 
diseases of X autosome translocations that will give you skewed X inactivation. 
Skewed X inactivation as a genetic trait independent of any other cytogenetic 
problem was subsequently found. I think we found an extended pedigree 
with that. That could complicate, again, what was going on in the family. 
But then there are just reasons for skewed X inactivations, some of which 
you can explain, some you can’t. One early explanation was twinning so that 
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when you have female monozygotic twins; the nature of when that twinning 
event happens, you can end up with poor sampling of the inner cell mass, 
so an ascertainment bias of sorts, so one girl would be highly skewed and 
could be severely affected and the other girl would bear normal and random 
X inactivation. We also found cases of it that almost seemed at the point 
of X inactivation – remember that’s 10 per cent of your genome – all those 
polymorphisms are now different between those cells, there seems to be an 
almost repulsion of two cells into a twin. We found cases where one twin 
had only the normal X active and the other twin had only the abnormal X 
active, so one was normal and one was Duchenne. So, as all the technology 
kept on advancing in parallel, like molecular assays for X inactivation, and 
all the international network of cases and case referrals, you really spread out 
and found more of a development of molecular epidemiology and molecular 
genetics explaining these unusual cases. 
Bushby:  Just to come back to the dystrophin testing again as well. We’d all been 
looking after some cases of young girls with severe muscular dystrophy, who 
didn’t have a translocation and who you really hadn’t reached a precise diagnosis 
in. Then, the ability to study dystrophin in the muscle biopsy really pushed us 
forward on that, so the ability to detect the mosaic pattern that you typically 
see in manifesting carriers was a real spur to our understanding of the fact that 
it wasn’t only these translocation cases that could be more severely affected, 
or more mildly affected carriers. Then we began to be able to look at them 
genetically and realized that it’s not unheard of to have these as new cases in the 
family – and I suppose in our Duchenne clinic now, there are probably about 
five relatively severely affected girls to 100 boys, say, and none of the girls have 
got translocations. We were, in a way, lucky that those translocation girls were 
picked up, because they’re not common. 
Temple:  And am I right in thinking there are muscular dystrophies that look 
very similar, but are not X-linked?
Bushby:  Yes, we had two of these girls in the clinic, and I remember vividly 
David Gardner-Medwin would say, just as Victor was saying, ‘This girl has 
got Duchenne, but apart from the mental profile, the learning profile and 
the neuropsychological profile are the same; however, this girl does not 
have Duchenne,’ although they were indistinguishable really apart from the 
neuropsychological profile. It did ultimately turn out that the second girl had a 
sarcoglycanopathy and the first one was a manifesting carrier. 
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Dr Rosaline Quinlivan:  I was just going to tell a similar story; I was just starting 
out in clinical practice in muscular dystrophy at the time, in the early 1990s, 
and it took quite a long time, I think, before we could diagnose girls who were 
manifesting carriers, to be able to confirm the diagnosis genetically. That took 
a long time after being able to do it with the boys. We had exactly the same 
experience with muscle biopsies, when there was patchy dystrophin staining 
seen on muscle biopsy in some patients, we thought they were manifesting 
carriers, but we had one girl who had a sarcoglycanopathy. So it was a more 
complicated picture.
Bushby:  In fact, if you look back at Louise’s report on that girl, her interpretation 
of that finding was that either this was a primary dystrophin abnormality or 
it was an abnormality of a protein that interacted with dystrophin. But that 
was prior to the discovery of the gene, so that was really quite an insightful 
comment, I think, at that stage. And, of course, she was working with the 
people – once those subtypes were identified – to get the antibodies to them as 
well, and then precisely make the diagnosis.
van Ommen:  One thing that’s entirely at the other end of the scale, to the 
girls with Duchenne or Duchenne-like, is – and I think that was one of the 
discoveries of Kay Davies – a man with a whopping Duchenne muscular 
dystrophy deletion, who has just been leading a productive life as a bricklayer 
Figure 11: Dr Rosaline Quinlivan
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and needed a walking stick when he was 61 years old.104 Then it turned out 
there was a similar patient found in Canada, and there were two more found 
in South America. So they’re extremely rare, but I think from the perspective 
of developing mini genes to try to just get towards the therapeutic end, these 
discoveries, as well as the discovery of the cognate gene, the utrophin gene, 
also by Kay Davies’ group,105 and also simultaneously, actually, by Lou Kunkel’s 
group;106 those two developments are complementing the complexity, but also 
the opportunities to do something about it. There was a French colleague of 
mine who listened to some of these things and then he said: ‘Oh well, this 
is actually a disease that wants to be cured.’ Of course, there are all sorts of 
things that put you on edge and also just contain the seeds of how to just think 
yourself out of a conundrum, into a solution.
Temple:  Absolutely. But this question about how people used to communicate 
at that time; was there an issue with competing commercial interest and patents? 
Was that something that was important in this community, in all your research 
groups?
Hoffman:  I guess I’m a co-inventor of some of those early patents.107 I think 
one of the key things that is discussed extensively in medical genetics and 
genes, and early on, was the idea that if patent officers were going to allow 
patenting of genes, they should be non-exclusive licences instead of exclusive 
licences. And certainly, that’s the path that this field took: to ensure that, if 
there were licences, they were not exclusive to anybody; you could buy them 
at a reasonable cost with reasonable royalties. That model leads to less money 
coming in. I can tell you as a co-inventor of the patent that maybe that meant 
two $100 cheques per year, when everybody was using the probes and the 
genes and the antibodies and everything; but it provides accessibility and at 
a reasonable cost. Certainly that there are other genes, like the breast cancer 
genes, that have gone in a different direction, and that became a very big 
controversy and led to an outcry to the point of where you can’t – at least, I 
think, in the USA now and other countries – patent a gene, because it’s pre-
existing; it’s not a composition of matter. 
104 England et al. (1990).
105 Helliwell et al. (1992) and Pearce et al. (1993).
106 Khurana et al. (1991).
107 See, for example, patent US5239060 A (entitled ‘Muscular dystrophy protein, dystrophin’) granted to 
Kunkel L M, Monaco A, Hoffman E P, and Koenig M; patent filed in 1987 and expired in 1997.
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So I think this field has generally sort of taken the high road for the longest 
time. There were a couple of hiccups recently with the exclusive licence for the 
DNA tests. I know they were trying to protect some of those, but the patents 
are running out anyway. I don’t think intellectual property (IP) and protection 
of IP was ever much of an issue in this field. 
van Ommen:  Of course, in the early days, many of the patents for testing for 
mutations in genes were conceived from the point of view that you would test 
in a focused fashion for one or more genes. There would be no way in the 
world that you could ever forbid someone to do a whole genome sequence 
and find whatever changes you will find. Perhaps it’s good to say a few words 
about HUGO in these days, the Human Genome Organisation.108 They had 
an IP Committee and an Ethics Committee, and one of the things that the IP 
Committee of HUGO already made clear very early on, is that you have different 
stages from discovery to invention: discovery is just finding something which 
was there and you hadn’t had any major specific contribution. Like the expressed 
sequence tags (ESTs): snippets of gene that, in fact, were first patented by the 
National Institutes of Health (NIH). The NIH gave the bad example. It was 
Bernardine Healy who told Craig Venter to patent his first 2,000 ESTs.109 Then 
the whole thing turned over and, interestingly enough, it was ten companies 
who actually battled, and together with two public laboratories, went against it 
and made all the sequences that they generated publicly accessible on a 24-hour 
basis after their discovery. So this was really the world in the reverse, where it 
was a public institution, the NIH, which started it, and several companies that 
actually went right through it and said: ‘We’re not in the business of patenting 
genes, we’re in the business of making drugs.’ So that was quite interesting, 
and it was then that in the early statements the HUGO IP Committee actually 
made very clear that when you were in the diagnostic arena and discovering 
mutations but had no functions attributed to the pieces of DNA that you were 
patenting, it was pretty pointless to patent this. By the time people had added 
their own intellectual contribution and found function and applicability, and 
had created value that somebody else might actually take on to further develop, 
then it became quite important to protect this IP, because it’s damn difficult 
108 For more details on HUGO, see McKusick (1989), as well as the Organisation’s website: www.hugo-
international.org (accessed 12 January 2017).
109 Bernardine Healy (1944–2011) served as Director of the NIH (1991–1993). Dr Craig Venter is a major 
contributor to the sequencing of the human genome; while an employee of the NIH, he submitted patent 
applications on ESTs, which caused a huge controversy; see Cook-Deegan (1994) and Roberts (1991).
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to develop drugs, and if you haven’t protected your IP, then the chance that 
something will come out of this is actually damaged if you don’t protect it. You 
can afterwards still decide that you’ll license it for a low amount, or for free, but 
at least you have the control of doing something about it, and negotiating with 
people that are interested to develop these into actual medicinal products. So 
that was the gradient that was identified, starting from low-IP discovery and 
ending in high-IP complex invention.110 
Temple:  We’re going to move on to the way that we’re now able to treat 
Duchenne muscular dystrophy, so are there others who want to comment? 
Muntoni:  This is a very quick one: you also mentioned the carriers, and what 
do we know about carriers, what do we do about carriers? One thing that is 
fascinating biologically – this is something that I did a little work on, but people 
in this room have done much more work there – it was possible to look at 
other ways to determine carriers on pathology and the dystrophin expression on 
muscle biopsies. I also did some experiments in animal models, and it was clear 
that what was mentioned, if you have a female with a random lyonization,111 
there will be at birth quite a significant number of dystrophin-negative fibres 
in the muscle biopsy, but because of the selective advantage of satellite cells 
that carry the dystrophin-positive but non-mutated allele, the muscle fibres will 
eventually lose most of the dystrophin-negative fibres to the point that it becomes 
quite challenging, unless you have a very skewed inactivation, to use pathology 
for the diagnosis of adult carriers. The drawback of this – and that’s probably 
why I was thinking about this – is that in the heart there is no regeneration, and 
therefore, what we have known for a long time, despite some early recalcitrant 
cardiologists, is that the risk of cardiomyopathy for carriers is not that for the 
general population because you cannot reverse the dystrophin negativity. If you 
look at the heart of carriers of mice, there will often be a mosaic as at birth, 
and this remains unchanged throughout life. This observation, and several case 
reports, and then population studies in Holland, in this country (UK) and 
other places, clearly identified a risk of dilated cardiomyopathy in carriers.112 
110 Professor Gert-Jan van Ommen added: ‘Which is why many diagnostic patents in those early days were 
not or hardly enforced. Except for the Myriad BRCA patents, and look where it has brought them.’ Note on 
draft transcript, 2 February 2016. This matter is discussed at length in Jones and Tansey (2014).
111 ‘Lyonization’ is another name for X-inactivation.
112 See, for example, Hoogerwaard et al. (1999b). Professor Bert Bakker commented: ‘First cardiac 
abnormalities were observed in Becker patients: Hoogerwaard et al. (1997); the carrier study followed in 
1999: Hoogerwaard et al. (1999a).’ E-mail to Dr Apostolos Zarros, 19 January 2017.
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This had led to a programme of regular cardiac surveillance that most of the 
clinical centres currently implement. I think that the risk of cardiomyopathy 
in carriers has been established to be approximately 8 per cent, or something 
around that number. 
Temple:  Did the European networks or the world networks make a difference? 
Muntoni:  I think the team, for example, of Katie, myself, and John Bourke, 
organized one of the European Neuromuscular Centre (ENMC) Workshops 
perhaps 15 years ago,113 maybe less than that. I think it was 2003. I think that this 
was, if you like, a network. There were no other ways than expert opinion at that 
time, and you had the representatives of many countries, and we started to look 
at the published evidence – at our own data set – and, actually, several studies 
were conceptualized at the time and grant applications were generated, including 
the one we are involved with in the UK, which is the randomized study of early 
intervention in Duchenne cardiomyopathy.114 Regarding carriers, one large survey 
on cardiomyopathy in carriers was published in the UK,115 and probably also one 
in Holland,116 where the risk of cardiomyopathy was, you know, found to range 
between 10 and 18 per cent. Eventually, many studies settled at approximately the 
same level, and that was the basis for implementing the current standard of care. 
Temple:  So the networking was important?
Muntoni:  Yes. 
Bushby:  The ENMC, which was set up through the interventions of various 
patients’ organizations under the initial leadership of Alan Emery, was a group 
of patient organizations who decided that a good way to spend their money – 
and I’m sure Victor was involved with this as well – was to get people together 
and sponsor research meetings where people could focus in a small group on 
a really small, but focused topic.117 I think my first one was your meeting on 
113 Bushby, Muntoni, and Bourke (2003).
114 Professor Francesco Muntoni commented: ‘This is a randomized, placebo-controlled study in which 
Duchenne muscular dystrophy boys with normal cardiac function are randomized to either receive placebo 
or cardioprotective medications (β-blockers and angiotensin-converting enzyme inhibitors).’ E-mail to Dr 
Apostolos Zarros, 17 January 2017.
115 Grain et al. (2001).
116 Hoogerwaard et al. (1999b).
117 For more details on ENMC, see Emery (1997), Rüdel, Nigro, and Poortman (2000), as well as the 
Centre’s website: www.enmc.org/home/ (accessed 12 January 2017).
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mosaicism in Duchenne in about 1991118 or something in the snow in Groningen 
before they (the ENMC) started moving to Naarden. Like Francesco said, these 
meetings have really led to lots of collaborations, the sharing of data, the sharing 
of patients, the sharing of findings that have then informed practice. 
Temple:  Okay, I think it’s been so interesting to have everyone’s opinion. We are 
now going to jump, although I would say it has been a natural progression, to 
how we’ve used these discoveries to try and make a difference to children with 
Duchenne muscular dystrophy, and how people came to the idea that we might be 
able to treat this muscular dystrophy using the knowledge of the structure of the 
gene. Is there anyone who might be able to take this story forward in some way?
van Ommen:  I wanted to prevent skipping over one thing, which is that the 
main therapeutic intervention that nowadays has really extended the life and 
also improved the health is actually the steroid treatment. Steroid treatment 
was – and Victor knows much more – really pioneered by Victor. There were 
countries where the steroid treatment for Duchenne was actually fiercely banned, 
like the Netherlands, and people would take their patients, people would come 
with their kids, to Victor to have the steroid treatment. So I think it’s important 
that that’s not missed and glossed over here. 
Temple:  Come on then, Victor, I think that’s a cue for you [laughter].
Dubowitz:  Well, it goes back to recent times, about 1986 I think it was, when 
the Americans – it was Mike Brooke, Mendell, Griggs, and a few others – they 
decided to do a controlled trial of steroids in Duchenne.119 They’d already set up 
a group to potentially look at treatments for muscular dystrophy further back, 
I think in about 1986 or thereabout, testing one placebo against another, and 
this was the first time that there was something that they were trying. They had 
some natural history outline already of the course of the medication and what 
they did was two doses of prednisone against a placebo.
Temple:  Do you know why they thought of it? Why did they think of using 
steroids?
Dubowitz:  Now the reason for that was that some years earlier there was a short 
paper in Lancet by Drachman and a chap called Ed Myer120 – I think I met up 
with him at one time in South Carolina or somewhere, but he was actually 
118 For more details on this workshop, see van Essen et al. (1992).
119 Brooke et al. (1987).
120 Drachman, Toyka, and Myer (1974).
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the person who had done the study together with Drachman – and they gave 
steroids in an open study, and it looked as though it was doing something 
useful, and they ended up by saying that there seems to be some benefit and that 
further studies are needed. What then surprised me, this was in the Lancet, they 
didn’t say ‘we are doing further studies’. They said ‘further studies are needed’, 
and so I was sceptical; I think many people were sceptical, why aren’t they 
doing it if it’s such an important breakthrough? And then it took about five 
years before Mike Brooke repeated some of the studies they had done, and then 
found that it was actually effective.
Now to fast forward, they did a very extensive study, with about 150 patients 
that were recruited.121 They weren’t very clearly defined so there were a lot of what 
they called outliers, which were milder cases and so on, and it was just a general 
diagnosis of Duchenne based on the clinical details. They found benefit from 
two dosage levels of steroid – a 0.75 and a 1.5 mg per kilo per day – and against 
the placebo, but those two were more or less the same, and so they recommended 
that the lower one was sufficient. But they said they couldn’t recommend it 
for use because of the side effects, which they had noted, particularly weight 
gaining. And there was a reluctance to use steroids in fact for quite a time and, 
for instance, in 1995 we had the first Workshop of the ENMC on steroids in 
Duchenne, and there were only seven centres in the whole of Europe that were 
using steroids at the time.122 And there was a reluctance in many centres to use 
it. And, in fact, as Gert-Jan has said, the three senior Dutch neurologists wrote 
to the medical journal in Holland and said: ‘There’s no evidence at all that we 
can see that steroids are of any use in muscular dystrophy, and we would strongly 
oppose their use,’ or something to that effect. They were very dogmatic about it. 
Anyway, then it took a bit of time and people were trying alternative dosage. 
Henriksson, for instance, in Sweden, was giving half of the recommended lower 
dose and said he was still getting some benefit,123 so that in a sense was the start 
of trying to adjust the dosage. We introduced an intermittent schedule because 
in all the original figures that Mike Brooke showed, there was an initial benefit 
and then a levelling off.124 So we thought: ‘If you get a benefit and levelling off, 
121 Mendell et al. (1989). 
122 47th ENMC International Workshop: Treatment of Muscular Dystrophy (13–15 December 1996, 
Naarden, The Netherlands).
123 Bäckman and Henriksson (1995).
124 Sansome, Royston, and Dubowitz (1993).
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why not just give it pulsed and then off?’ So we gave it once a month for 10 
days and then off and, by day 20, the kids were saying they were feeling weaker 
again, so we started 10 on, 10 off. So that’s continued, and there have been 
benefits and disadvantages; the benefits being that they get some responses and 
some of the young ones – particularly under five – seem to lose almost all sign 
of any weakness, to go on for quite a time.125 Then it’s mainly with the growth 
spurt that they tend to lose ambulation, and it’s also with the growth spurt that 
they seem to go rapidly downhill. 
The long-term continuous steroid has shown a longer duration of ambulation 
compared to the intermittent by about two years on average, but also a stunting 
of growth, which is probably one factor in them not getting worse in that critical 
growth period. And so it’s a toss-up between the quite substantial steroid side 
effects, and trying to avoid side effects by alternative dosage schedules. It’s still 
an ongoing controversy, and Kate Bushby might be able to tell you about the 
ongoing study of the continuous versus the intermittent, which has been set 
up.126 So that’s the position with steroids, but there’s no question that it’s made a 
big difference.127 Now I should also mention, when we talk about management, 
that the main thing with Duchenne is once they go off their feet they very 
rapidly get scoliosis, and that’s because they have a growth spurt at the time they 
go off their feet, there’s increased spinal growth and they’re in a sitting position, 
and they very rapidly tend to get a progressive scoliosis. If you can keep them 
walking through puberty and their growth spurt, they in fact have very much 
less risk of scoliosis. 
Temple:  Did you observe that?
Dubowitz:  This again has a history, because in the 1950s already and 1960s, 
Vignos, a neurologist in Cleveland, ran a rehabilitation centre, and there were 
spastic children and other children; he tried putting calipers on to children 
with muscular dystrophy, but they couldn’t cope with them because they were 
too heavy.128 It was the old leg irons. In fact we tried them in Sheffield in the 
1960s, and it was the same problem because these things were too heavy. Then 
there was Siegel, who was an orthopaedic surgeon in the States, in Chicago, and 
125 Kinali et al. (2002).
126 Bushby et al. (2004).
127 See also, Dubowitz (1991), (2013) and Ricotti, Ridout, and Muntoni (2013).
128 Vignos and Archibald (1960) and Spencer and Vignos (1962).
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Silverman, who was a very clever orthoptist; they designed a polypropylene 
moulded, very light-weight prosthesis with ischial hip support, and he got these 
kids mobile in these supports.129 That’s at the time of losing ambulation. So 
we introduced that as well and around about the early 1980s, I think it must 
have been in the 1970s. On the first consecutive series of 57 cases, we actually 
achieved an average of two to three years of extra ambulation, and much less 
scoliosis.130 So that was a physical means of promoting ambulation beyond the 
usual time of loss. 
The important thing there was to be able to keep going through the growth 
spurt, and once you got to that and they got into the sedentary position, they 
were much less likely to get scoliosis. And it was much easier to control. Then, 
of course, when steroids came, it really achieved the same, because it kept them 
ambulant through their period of growth spurt and then managed to continue. 
So it’s a question always of any drug you give – there are no free lunches – there 
are always side effects, but you’ve got to weigh the potential benefits against the 
side effects. So, basically, and, of course, there’s also the support of treatment. 
As I mentioned in the beginning, in the 1950s nothing was done essentially for 
these children in any sort of rehabilitation, so there’s a lot you can prevent from 
an early stage with proper management and just simple things. So that’s more 
or less an overview.
Quinlivan:  I would go a step before steroids. The step before steroids was the 
introduction of non-invasive ventilation, and when I was at Guy’s we started 
looking into this in about 1990/91; at the Hammersmith, Victor had already 
started using it on his patients.131 But still there was a reluctance among the 
community to accept it as a good intervention. People were arguing about quality 
of life and extending life, and there were lots of discussions. And even in, I think 
it was 1995 or 1996, I attended a workshop that was set up by Richard Edwards,132 
who was working in Liverpool at the time, because, even at that point, there 
were still people reluctant to start non-invasive ventilation and, of course, now we 
know that that’s resulting in a very marked extension in life expectancy.
129 Siegel (1977).
130 Heckmatt et al. (1985).
131 Heckmatt, Loh, and Dubowitz (1990).
132 The ‘Consensus Workshop on the role of non-invasive ventilation in the care of patients with muscular 
dystrophy’ took place at the Royal Liverpool University Hospital on April 1996. It was chaired by Professor 
Richard Edwards, and sponsored by the Muscular Dystrophy Campaign.
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Temple:  What do patients think about that?
Quinlivan:  Well, the patients like it as soon as they are treated with it. Because 
at the time we were treating people when they became symptomatic. Now we 
don’t wait that long, but, of course, they felt much better when they started 
using it. It actually started to improve their quality of life.
Temple:  It wasn’t families that were resistant, it was health professionals?
Quinlivan:  It was health professionals, and it was their opinion about quality of 
life. So it was their opinion about what was good quality of life.
Dubowitz:  If I could just add a supplement to that actually, because there are 
two sides to the coin and, I think, part of the problem in the earlier days was 
when they got to about 16 or 17, they suddenly went into respiratory failure 
and very often died within three to six months. The choice, then, was do we put 
you on a ventilator for life with a tracheostomy or do we just let things go? And 
very often the families wouldn’t accept this. In some countries they already had 
established units, where they were doing a lot of tracheostomies and the family 
almost had to do supportive care, nursing, and come and look after. And Rancho 
Los Amigos, an orthopaedic centre for rehabilitation in California, they were 
also doing tracheostomies as common practice.133 What really changed the whole 
scene in the 1980s was the realization that it is the diaphragmatic weakness that 
gives you failure at that stage, and if you take a proper history, they’re getting 
headaches, they’re restless at night, they have disturbed sleep, and when non-
invasive mask ventilation was introduced, I think it was in the 1980s, it made a 
dramatic difference, and suddenly these children were not only better sleeping at 
night, but also during the day, and the parents said it was a different child.134 
Temple:  Who thought of the mask, do you think?
Dubowitz:  I think it was introduced by respiratory people; I don’t know exactly 
where, but it started being applied to things like Duchenne. When John Heckmatt 
was with us at the Hammersmith, he got very interested and he actually started 
putting the Duchenne boys on to nocturnal ventilation with ventilators at home, 
and he would actually provide an on-call service to go and adjust the ventilators.135 
133 The Rancho Los Amigos National Rehabilitation Center is a rehabilitation hospital located in Downey, 
California, USA.
134 Bach et al. (1987). 
135 Heckmatt (1987).
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We had about 25 children at one time on ventilators, and there was also another 
doctor who did some basic work in relation to this, so I think this became very 
viable. What was interesting was that the parents came back and just said, you 
know, the child is just so much better generally, and then they would go on 
till their twenties and then, of course, came a point in time where they needed 
the mask by day, not just by night, and then, eventually, might end up with a 
tracheostomy as a final stage. But certainly that transition in the late 1980s or 
thereabouts, I think, made a tremendous difference to many of these patients. 
Then we set up a link with the Royal Brompton Hospital, and had a monthly 
clinic, and they gradually took over the care of the respiratory side so that it 
evolved as a service. 
Temple:  And is that how it is today?
Dubowitz:  Yes, I think it still is; in most centres they’d certainly still be doing the 
non-invasive mask, which has been applied to many other conditions. There are 
some congenital myopathies that die suddenly, although they’re doing quite well 
physically, simply because they have diaphragmatic weakness selectively – so that’s 
important to diagnose and save them.
Bushby:  I think that Victor started by talking about the era of neglect, when doctors 
would say to people with Duchenne: ‘Just go away and love your son, and there’s 
nothing that you can do.’ I think that all of us would now be very strongly arguing 
for a very proactive way of treatment, thinking about the possible complications, 
understanding how to manage them properly, the right introduction of the right 
steroid at the right time, planning for the respiratory monitoring that will allow 
you to pick up respiratory failure before it’s a problem, before it’s symptomatic, 
allowing monitoring of the heart so that you’re treating before there’s any risk 
of symptoms. Patients are symptomatic only very late with heart problems, so 
you really want to pick them up very early by using increasingly sophisticated 
techniques, and so forth. I think that what that’s boiled down to is that now, when 
we make a diagnosis, we actually talk about adulthood; we talk about planning 
for adulthood, and we talk about hope for not only, as we’re going to come on 
to – new therapies – but also what the current therapies can do for these patients 
and for families. So, certainly, I can remember the days when we used to bring 
people in and give the diagnosis of Duchenne, and you’d have them in, do the 
biopsy, you’d have the dystrophin stain; you’d be giving this terrible diagnosis. I 
can remember one day when we had three in a row, and the third parent actually 
turned around to the team and said to us: ‘How awful that you have to do this 
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three times in one day.’ The parent said this to us. Of course, it was such an 
awfully humbling thing to happen. But now, although it’s still a horrible diagnosis 
– a devastating diagnosis, and the family never is the same again following the 
diagnosis – at least you can talk about being proactive, making sure the right 
things are put in place so that the family can get on with their lives and you can 
have a proactive plan to look after the child from a medical and social perspective.
Temple:  So how did it come about that we’ve got potential gene therapy in this 
disorder? 
van Ommen:  One thing that got it started, of course, was the difference between 
the Duchenne and the Becker muscular dystrophy, because that created in several 
places almost simultaneously – in Leiden, in London, in Australia, in Japan – the 
idea ‘What if we could actually turn Duchenne into Becker?’ So that was the 
idea. I remember, I just don’t know precisely what year, but we were travelling 
through Japan for vacation and then I was invited to Kobe by Matsuo.136 He 
had this peculiar patient that had a deletion of well-counted 19 base pairs inside 
one exon, or maybe 50 base pairs or whatever, but a small amount of base pairs 
within one exon, and he said: ‘I’m trying like crazy to just PCR (polymerase chain 
reaction) this exon to show that it is shorter and I just can’t get it amplified.’137 So 
then I told him: ‘You know what I think happens? I think that the deletion in that 
exon actually changes the secondary structure of that exon in such a way that the 
exon is not recognized as exon anymore.’ That was what, on the way there and 
on the way back, got me thinking. Following the genomics also quite closely, I 
had this kind of idea, ‘It can’t be that the splicing machinery will read 2.5 million 
base pairs of RNA from beginning to end to see what splice signals it will meet; 
there are too many spurious pseudo-splice signals.’ So there must be a two-step 
mechanism as it were: one that sort of identifies these exons as perhaps secondary 
structure or protein-containing balls or whatever, sort of too few pearls on a far 
too long string, and some mechanism then just sort of gets all the pearls together, 
and a second step would be the actual splicing that removes the excess of string 
between the pearls. So I reasoned that if you would make the pearls no longer 
look like pearls (which is what happened with this tiny deletion in my view). For 
example, you should take a big hammer and kill one of the pearls, and you might 
just get the thing back in frame. 
136 Professor Masafumi Matsuo is a Professor in the Department of Medical Rehabilitation, Kobe Gakuin 
University and was Professor of Paediatrics at the School of Medicine of Kobe University (1992–2011). 
137 Matsuo et al. (1990, 1991).
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So that was our idea, and we had this ongoing debate between different groups 
on: ‘Do you actually target for the splice sites or do you target for the internal 
regions of the exons?’ Our view in Leiden was: ‘Let’s target the inside of the exons 
by doing something there to sort of “unexonize” it.’ Several other groups had 
similar schemas, but they were targeting the splice site to interfere with the actual 
splicing recognition. In our view that was sort of basically hitting the second part 
of the machinery and causing the machinery perhaps to start scratching its head 
– ‘What was going on there?’ – and skip more exons than only that specific one. 
So that was at the beginning, the argumentation in the field: do you target splice 
sites or do you target internal? But somehow you had to do something to remove 
exons from the RNA to actually get the gene back in frame. And so there’s another 
person in our laboratory who is very inventive in that field, Johan den Dunnen.138 
Johan and I sat together and we just worked out schemas for many of those exons 
to see if we could do it this way. Then we wrote an application to the Muscular 
Dystrophy Campaign in England and it had two plans: one was to make a mouse 
with a human Duchenne gene, and the second plan was to see if this exon skipping 
would work. I was also on their Scientific Committee, but I had to stand in the 
hall, of course, for my own application. Then the verdict of the whole thing was: 
‘you will get your money but you shouldn’t do this exon skipping because it’s a 
nice idea, but it’s not going to work. You will get your money for making the 
dystrophic mouse or at least the hDMD mouse.’139 So then we decided to turn to 
the Dutch patient association, and we got money from them a year later, and at 
the same time had already started. And in fact both worked – the mouse with the 
human dystrophin gene and the skipping one140 – but that was basically how it got 
started, and in 1996/1997 it materialized. And before 2000, 1999, or so, we had 
the first patient cells treated with antisense oligonucleotides.141
Judith van Deutekom142 started on this work in 1998, and then we just got through 
the early stages, and we had to get in touch with the Amsterdam medical centre 
138 Professor Johan den Dunnen is Professor of Medical Genomics and Head of the Leiden Genome 
Technology Center at the Leiden University Medical Center; see www.nbic.nl/about-nbic/nbic-faculty/
details/dunnen-den-johan-t-prof-dr/ (accessed 12 January 2017).
139 The abbreviation hDMD stands for the ‘humanized’ Duchenne muscular dystrophy gene.
140 Bremmer-Bout et al. (2004) and ’t Hoen et al. (2008).
141 van Deutekom et al. (2001).
142 Dr Judith van Deutekom is a molecular biologist and was project leader of the Duchenne Muscular 
Dystrophy Genetic Therapy Group at the Leiden University Medical Center. She later became the Head of 
Research of Prosensa BV, and is now Vice President (Drug Discovery) of BioMarin Nederland BV (formerly 
Prosensa Therapeutics BV).
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for cells from patients with specific correctable deletions. We looked at what exon 
would be the best target, and that was exon 51, because there were many deletions 
that ended in exon 51 and if you would remove exon 51, you would kick it back 
into the Becker frame.143 So that was where we targeted. I know that in Francesco’s 
group they were at the same time – even earlier – doing this with the mdx mouse.144 
So how it precisely is from day to day I only know from our study, but it was 
approximately 1999/2000 when we managed to get the first skip in cultured 
patient cells. Then we just repeated the thing with six different types of deletions 
in six different patient cells, and all six showed the same result, and that was in 
2002.145 So in 2000, I think in September 2000, was our first patent application 
before submitting the publication for the first human skip.
Dr Michael Gait:  I just wanted to ask a question, Gert-Jan. Ryszard Kole from 
the University of North Carolina was also working in splice switching in the 
late 1990s and had been doing work with β-globin gene and thalassaemia 
143 Aartsma-Rus et al. (2003). 
144 The mdx mouse simulates a mild form of Duchenne muscular dystrophy, by bearing a point mutation 
in its dystrophin gene, and thus expressing a small, non-functional protein. For more details, see Partridge 
(2013).
145 Aartsma-Rus et al. (2003).
Figure 12: Dr Michael Gait
The Therapeutic Implications of Muscular Dystrophy Genomics
52
genes.146 I wondered, from the historical point of view, whether your work 
predated that of Ryszard Kole, or whether Ryszard Kole’s idea of using 
oligonucleotides to splice switch came first? Have you any comments on that, 
because I don’t actually know which idea came first.
Professor George Dickson:  I would say, from my opinion, that Ryszard Kole first 
published this observation of exon skipping using antisense oligonucleotides.147 
It was his published observations in the globin system that triggered many of 
the groups to think about exon skipping in the context of Duchenne, and, as 
far as I know, my own group and Steve Wilton’s group began to look at this,148 
something we really first published back in the mid-1990s; 1995, 1996 were the 
first publications that I am aware of. But I have to say that I agree with Mike 
[Gait]: I think Ryszard’s work triggered us to look at the dystrophin gene and 
whether we could do something similar in that model. And most of that work 
was performed in the mdx mouse model in particular and then, as Gert-Jan says, 
the Leiden team and our own picked up that work in the context of human 
Duchenne muscular dystrophy patient cells and demonstrated that the same exon 
146 See, for example, Sierakowska et al. (1996). Ryszard Kole is a Distinguished Scientist at Sarepta 
Therapeutics; he has previously served as Professor of Pharmacology at the University of North Carolina at 
Chapel Hill.
147 Dominski and Kole (1993, 1994).
148 Dunckley et al. (1998) and Wilton et al. (1999).
Figure 13: Professor George Dickson
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skipping could be achieved in these patient cells. I agree with what Gert-Jan says: 
when this was first presented in the scientific community, there was significant 
scepticism. Certainly there is one scientist here in London, I can remember, who 
told me his opinion that if this ever worked in a therapeutic context that he would 
eat his hat [laughter]. So maybe I’ll talk to him about that, maybe in six months’ 
time, Gert-Jan. That’s my view of the early historical perspective.
Temple:  Who was it that said they’d eat their hat?
Dickson:  I don’t think I should mention that.
Temple:  Well, I don’t think it matters. We’re among friends and it’s going to be 
published [laughter].
Professor Terence Partridge:  It might well have been me if I’d worn a hat.149 
At the time, I remember, I saw George’s stuff and Steve Wilton’s work, and I 
thought it was something that would interest people who were interested in 
PCR, because that’s by and large what people were looking at. There’s another 
149 Professor Terence Partridge added: ‘One point that should be considered as an addendum to the Witness 
meeting is the fact that the discovery of the dystrophin protein set off a series of discoveries of the genetic 
causes of various congenital and limb-girdle dystrophies associated with defects in the genes encoding the 
other proteins in the complex of which dystrophin was the central organizer. This work came mainly from 
Kevin Campbell’s laboratory, and was a very good illustrative example of how a single discovery can seed a 
cascade of further discoveries.’ Note added with draft transcript corrections, 2 February 2016.
Figure 14: Professor Terence Partridge
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thing we’ve actually skipped a little bit, which is that the other main therapeutic 
push at the time was the idea of stem cells. So we got into both sides really via 
our collaborations with Eric Hoffman, because I worked for a long while for a 
man who was obsessed with the idea of circulating muscle stem cells, and we 
spent a lot of time showing it didn’t work.150 But whereas you could actually 
directly inject stem cells into muscle – Jenny Morgan and I worked for about 
20 years on this – I think, altogether, that we didn’t have a good model. We 
didn’t have a mouse we could cure of anything, for a long while. We cured a 
mouse of phosphorylase kinase deficiency, I think, at one stage, but it has no 
pathology.151
The idea of transplanting cells to see whether it would do anything was very 
marginal, it must be said, and it’s still a bit of a mystery there. Anyway, we 
didn’t have a model. There was another mouse model called the dy mouse,152 
which we steered very clear of, because it plainly had a neuropathology as well 
as a muscle pathology, and we thought we would run into confusing results. 
The man who did cure that mouse eventually sold his stem cell therapy for 
$150,000 a go, and I think sued Eric and me for $11 million, at one stage, 
because of our comments on it [laughter].
Temple:  Can we have the name of that person?
Partridge:  A man called Peter Law.
Temple:  How interesting.
Partridge:  Anyway, I got into that because we’d been working on the mdx 
mouse153 on the basis that it was the only possible model of Duchenne 
muscular dystrophy, because it was X-linked and it had a pathology that we 
could identify, and we did lots of experiments; we built up a whole bunch of 
mice with extra markers in, because we weren’t quite sure what we’d be looking 
at, so we needed iso-enzyme markers to show that we’d done what we thought 
we’d done. Then Eric turned up with the antibody – the first access that we had 
to an antibody to dystrophin – and so we sent our stuff across the Atlantic and 
he found lots of results from our stem cell transplants. 
150 Partridge et al. (1989).
151 Morgan et al. (1988).
152 See, for example, Meier and Southard (1970).
153 Bulfield et al. (1984).
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Temple:  What year are we talking about?
Partridge:  1987. And at the same time we actually found – also with Eric’s 
antibody – the ‘phenomenon of reversion’ as it’s called.154 So you get revertant 
fibres, so that even though these mice have a disabled dystrophin gene they 
make little patches of dystrophin-positive fibres, and that’s still a fascinating 
area because we don’t understand it – at least I don’t understand it. But that 
tooled us up really to get into the exon skipping field because we had a very 
bright man – we employed him as a technician – a man called Qi Lu, who 
turned out to be much cleverer than the rest of us, and developed good ways of 
blocking.155 When you look with monoclonal antibodies, especially on mouse 
tissue, you are stuck with the fact that the mouse is already full of antibodies, and 
he developed good ways of blocking the background for tracing monoclonals 
in the mouse. It turned into a commercial reagent called ‘mouse on mouse’, I 
think, which most people use for blocking. Anyway, so we were well set up to 
look at the exon skipping when it was being done, and I think we were the first 
group to show convincingly that you actually got dystrophin in the muscles 
when you skipped exons in the muscles.156 
Temple:  And how were you doing exon skipping?
Partridge:  We were collaborating with Steve Wilton, so we were using his 
reagents – it was the 2'-O-methyl phosphorothioate chemical we were using at 
the time. And the reason we got it working and, I think, other people didn’t, 
was that we used a carrier: so we had a carrier that would get it into the muscle 
cells; it gets very poorly into muscle cells in vivo, much better in vitro, which 
again is a mystery.
Temple:  How did you design the carrier?
Partridge:  We looked around for things that worked as carriers, it was a block 
co-polymer with hydrophilic and hydrophobic regions, and so we saw them. 
You can see them without the carrier, but you have to look very hard and be 
very convinced they are there. I think that’s what you found, wasn’t it? And so 
we actually got into both fields really via our collaboration with Eric, in the first 
place. 
154 Hoffman et al. (1990).
155 Lu and Partridge (1998).
156 Lu et al. (2000).
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Dickson:  I think the other interesting point to make back in those days was 
that the two chemistries that were being developed for the antisense field, 
the 2'-O-methyl phosphorothioate and morpholino chemistries. So there 
were, and are, at least two different chemistries doing the same thing in an 
antisense context. I think one of the reasons we had a lot of difficulties in those 
days in the mdx mouse was that we were all working with the 2'-O-methyl 
phosphorothioate chemistry, and it turns out that in the mouse that chemistry 
works much less well than the morpholino chemistry. Obviously, then followed 
Terry’s work, using a carrier to develop and improve delivery, and so eventually 
there were studies done with the morpholino chemistry in the mdx mouse. 
The difference between the 2'-O-methyl and the morpholino chemistries in 
the mouse was an unexpected situation, and perhaps in the human there may 
be a different scenario.
Temple:  A problem always with mice, or any sort of model potentially.
Dickson:  I think that’s correct. So there is an issue of distribution in the animal 
model. Certainly those morpholino responses in the mouse were much better, 
and most groups including the Leiden group, I think, had the same data showing 
that in the animal model the morpholino chemistry is better in a dose-related 
sense.157 But, obviously, the clinical trials that are running now in Duchenne 
muscular dystrophy patients are looking at both chemistries, almost in a close 
competitive manner.
Partridge:  I think the dichotomy of disparity between the morpholino and the 
2'-O-methyl phosphorothioate, in vivo and in vitro, is really curious, because 
you can’t get morpholinos into cells in tissue culture, whereas the 2'-O-methyl 
phosphorothioate goes in fairly easily, and the converse is true – certainly with 
systemic delivery – in the mouse. I don’t think anyone has come up with a 
decent explanation of that yet.
van Ommen:  Well, there are at least some thoughts about it; just for the 
record I fully agree with Ryszard Kole working on the globin gene years earlier 
than this, and that was where the whole field got the idea for how actually 
to skip an exon using oligonucleotides. I think that’s clear that they really set 
this whole field going. Now on the morpholinos versus the 2'-O-methyl or 
157 Professor Gert-Jan van Ommen commented: ‘This is still an ongoing fight and George Dickson is 
misrepresenting Leiden here. We actually showed that which chemistry was better depended on the actual 
antisense oligonucleotide sequence and exon to be skipped.’ Note on draft transcript, 2 February 2016.
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later generations, if you listen to the recent talks of ISIS,158 there are very many 
promising modifications in the backbone that increase the uptake or decrease 
the toxicity and increase the lifetime. Why are they different? Some people 
think morpholinos are neutrally charged, and so, in vivo neutrally charged 
molecules go more easily in and out of tissues than negatively charged molecules 
like 2'-O-methyl. And with regards to 2'-O-methyl, if you want to transfect 
cells then you can use a transfection agent to get the 2'-O-methyl properly in 
place. So if you do it in your model development in cell culture, then you can 
use all sorts of transfection agents to get negatively charged molecules in. So 
that part of the difference between the two has to do with the fact that they’re 
charged or not. That, sometimes, is even being used in investor language to 
bias lay people by saying: ‘Ours are neutral and the other ones are negative.’ 
You know, that ‘odourless liquid, dihydrogen monoxide, which is pumped by 
governments through underground tubes into all the houses without anyone 
knowing it.’ Well, that’s water. It’s just how you phrase it. 
I really think that we all have many rounds of further discovery of the 
technologies, and it might even be depending on the sequence; that’s what comes 
out of the recent talks of ISIS that there are actually still not yet well-understood 
sequence dependencies that may make some sequences more toxic, and some 
sequences less toxic, and some sequences working better in this backbone, and 
other sequences working better in the other backbone. So I think that that’s still 
up there, and that’s probably something that you [Michael Gait] could say a lot 
about.
Gait:  I think that the chemistry differences between the 2'-O-methyl 
phosphorothioates and the morpholinos are profound. The reason the 
2'-O-methyl phosphorothioates are active at all, is really because of very good 
protein binding, particularly to serum albumin and other serum proteins 
of that nature, which delays their excretion into the kidneys. Particularly 
phosphorothioate oligonucleotides go primarily to the liver and kidneys, but 
they are slowed down because of the binding of the phosphorothioate, the 
sulphur atom, to these proteins, and that’s why it gives them more time to be 
able to enter muscle cells and other cell types. By contrast, the morpholinos, 
being charged neutral, go into muscle cells, but they are excreted even faster 
than a phosphorothioate. And they are excreted into the kidney and end up 
158 ISIS Pharmaceuticals (widely known as ISIS), called ‘Ionis Pharmaceuticals’ since December 2015, is a 
pharmaceutical company based in California, working on antisense technology; for more details, see www.
ionispharma.com (accessed 13 January 2017).
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mostly there. I think that the advantage of the morpholinos is also that they are 
completely non-degraded, so they are excreted whole, and therefore not very 
toxic; in fact hardly toxic at all. Therefore they’ve been able to go up to very high 
doses in clinical trials – 30 mg/kg, 50 mg/kg – and that is the salient feature 
of the morpholinos, the high dosing. But it makes them very, very expensive as 
well, and that’s the problem. In the case of 2'-O-methyl phosphorothioate, these 
can be mixed with other nucleotide analogues such as the C-ethyls: the various 
types that ISIS Pharmaceuticals have, which have a better pharmacology, higher 
binding to the target RNA, etc., and these will provide second generation oligos 
in due course. In the case of the morpholinos, work that we’re doing with 
the University of Oxford and also separate studies being done by Sarepta,159 is 
adding peptides to the morpholinos, which helps to get them even better into 
muscle cells, and to reduce their excretion to the kidneys. So there are many 
chemical changes, and you’re absolutely right that these exploratory chemical 
changes will certainly make these oligo drugs much better in second and third 
generations; I think that’s clear.
Temple:  How did we go from making the cell-line to the clinical trials? How 
did that progression happen?
Partridge:  We developed immortalized cell-lines of mice, including the 
dystrophic mouse and other mice. Jenny Morgan did all this. They were heavily 
used at least for defining what the best target molecules were. Steve Wilson 
used them – we sent them to Australia. I don’t know whether you’re still using 
them at all? The other thing was that in the mouse we were very lucky that the 
mutation is in exon 23, and I think there’s a whole bunch of downstream exons 
that are in frame; so what we see under the microscope might contain a number 
of different skips. George [Dickson], I think, showed that there is more than one 
skip when you hit exon 23. Certainly the frequency of spontaneous revertants 
in that mouse are much higher than any other mutation we’ve seen. So it may 
be a particularly serendipitous mouse. The cell-line stuff: Jenny Morgan has 
done most of the more recent development I know of, looking at cell-lines; and 
Giulio Cossu, who is not here but lives in Manchester these days, has developed 
the idea of cell transplantation more fully than we did.160
159 Sarepta Therapeutics is a pharmaceutical company based in Massachusetts, working on morpholino 
oligomers; for more details, see www.sarepta.com (accessed 13 January 2017).
160 Professor Giulio Cossu is Professor of Regenerative Medicine at the University of Manchester; see www.
manchester.ac.uk/research/Giulio.cossu/ (accessed 13 January 2017).
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Professor Jennifer Morgan:  I think Francesco can say more about it. We’ve 
been using human cells; I haven’t been using the mdx cell-line to test antisense 
oligonucleotides in vitro. We have used patient fibroblasts that are converted 
into myogenesis, for screening antisense oligonucleotides.161 
Muntoni:  The ENMC was mentioned before, and I think it’s appropriate to be 
mentioning it again, because at the time – I’m thinking now 2003/2004 – there 
had been a consolidated network in the Dutch consortium, if you like, where 
preparatory work for a clinical trial was clearly building with the realization of 
the potential that Gert-Jan has mentioned before. There was a mature effort 
from Steve Wilton in Australia, who had been working for quite a number of 
years in animal models; there was very mature work from Terry, from George, 
and other people in the UK. And, together with Gert-Jan, we hosted a series of 
ENMC Workshops in order to discuss competition and collaboration, if you 
like.162 Initially, it was interesting because a lot of parents were concerned that it 
was a waste of time that two consortia would do some work that was relatively 
similar – if you look at it from a distance – because we all wanted to achieve exon 
skipping with antisense oligonucleotides. Actually we chose to look for the most 
common mutation that was exon skipping, exon 51, but at least we discussed 
why we would do that, what would be the type of study design we would do, to 
161 See, for example, Zhou et al. (2013).
162 See, for example, Muntoni, Bushby, and van Ommen (2005).
Figure 15: Professor Jennifer Morgan
The Therapeutic Implications of Muscular Dystrophy Genomics
60
try to at least have them reasonably aligned so that we could have some mutual 
understanding of what was going on. And that, I think, was certainly for me 
very, very useful. I was, in fact, the clinician involved in the UK study, together 
with Kate [Bushby], to put together a protocol for taking forward one of these 
two chemistries in the UK. Just to give an idea how naive we were: we decided 
about the chemistry – and this was the morpholino chemistry – and we decided 
this without asking the company whether they were interested in supporting 
this chemistry or not. As it turned out this company would certainly not exist 
today if we didn’t draw them in the Duchenne field, and I don’t think this is 
an understatement. But I think we were very, very naive. We wrote a protocol 
together with many people here in the room and Nic Wells,163 who is not in the 
room, who also gave a lot of help with the first-in-man clinical trial using the 
morpholino, using a protocol that was quite similar, with some differences, to a 
protocol that colleagues in Holland have used. The colleagues in Holland were 
ahead of us, especially in the first-in-man study – you published it probably a 
good year and a half before our study was published, and so you clearly were 
ahead;164 you especially had a very good collaboration with one particular 
company.165 You may want to explain it because it was, if you like, a spin-off of 
an academic collaboration, while we had to find this company in the States.166 In 
both consortia, we both did first-in-man by selecting a small group of children 
in whom we would demonstrate that whatever happened in the mice also 
happened in humans, in boys. After a single intramuscular injection we were 
concerned initially: does it work at all, does it do any harm? There was a lot of 
concern, theoretical concern, that you may trigger auto-immunity, for example, 
and therefore we wanted to make sure before thinking about a systemic delivery 
that we were not damaging muscle. Both consortia used a slightly different study 
design, but, in a sense, very similar ideas. Both consortia then moved to the next 
step, which was the systemic delivery, having demonstrated proof-of-concept of 
163 Professor Dominic (Nic) Wells is Professor in Translational Medicine at the Royal Veterinary College, 
University of London; he has previously been Professor at Imperial College, London (2005–2010); see 
www.rvc.ac.uk/about/our-people/dominic-wells (accessed 13 January 2017).
164 van Deutekom et al. (2007) and Kinali et al. (2009).
165 Five of the authors of the van Deutekom et al. (2007) study report being employed by or having an equity 
interest in Prosensa BV, which has taken PRO051 into clinical development for the treatment of patients 
with Duchenne’s muscular dystrophy. See also note 142.
166 Dr Ryszard Kole, co-author of Kinali et al. (2009), joined AVI BioPharma in 2008 as a Senior Vice 
President of Discovery Research; see also note 146.
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a single injection that was safe and that appeared to do in the human the same 
that it did in the mice. The two chemistries did eventually demonstrate proof-
of-concept by systemic repeated injection of the two different chemistries.167
Temple:  So there were separate groups doing the same thing, but you’d agreed 
that you would both try and start with the treatment of people with the same 
type of mutation?
Muntoni:  Yes. We had a number of workshops where we really discussed it in 
detail; we actually made some slightly different choices: for example, of the 
muscle to biopsy, and so on and so forth. However, eventually, we used the same 
antibodies to detect efficacy of the result, and, more than anything else, there 
was a lot of cross-fertilization, a lot of ideas; you know you run through ideas 
in a safe environment in somebody’s workshop where you can think about a 
stupid thing, and then you probe it with colleagues and then colleagues will tell 
you: ‘Well, actually Francesco, this is a very bad idea,’ and then you wouldn’t 
develop this further.
Temple:  And you had patients who would take part in your early trials?
Muntoni:  Yes. So, patients actually took part as active participants in the 
consortium. Our consortium, apart from academic representation, first 
obtained a grant from the Department of Health in 2004, and then another 
grant from the Medical Research Council (MRC) in 2008, for the two different 
studies. For the first study, the parent association was a member of the scientific 
consortium, the people who wrote the grant with us, so we had the patient 
representation all the way through from the very beginning. I know, as a fact, 
it’s very similar to the work that Gert-Jan has done in Holland, together with 
a Belgian group, and so on, and so forth. But I think the ENMC Workshops 
allowed us to – we knew we were going to do something similar, why don’t we 
discuss it? You know there is enough space for it; well, there will be things to be 
learned by doing it. I think, in a way, I’m glad that we did it in the way that we 
did. I think it is useful to have two chemistries moving forward; each of these 
chemistries will probably have their own limitations, these are first generation 
antisense oligonucleotides, and I think we did the right thing the way we did it. 
van Ommen:  I can only echo that there were patient associations, or representatives 
from the patient associations, from both the UK and from the Netherlands in the 
ENMC Workshops. And there was even quite a fiery debate between the patient 
167 Cirak et al. (2011) and Goemans et al. (2011).
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associations. Some people were of the opinion that it would be a waste to just do 
these two trials, but others were clearly of the opinion that you would learn more, 
because you find that something works differently in one way and something else 
works differently in the other way. We had, from the early days on, a company 
involved, Prosensa, that was actually a Leiden spin-off company, initially broadly 
focused on biomolecules.168 It was founded by somebody who synthesized many 
oligonucleotides in the Netherlands, called Jacques van Boom.169 And there were 
two other company people involved: one was Gerard Platenburg and the other 
one was Herman de Boer, who made the first genetically modified bull with an 
extra lactoferrin gene, and caused a major debate in the Netherlands.170 They all 
left the biotech company Pharming, and they had established a tiny company, 
end of 2002; and then I had an adviser for our genome centre, the Centre for 
Medical Systems Biology (CMSB),171 Otto Postma, who also came from the same 
company (Pharming). It was a sort of big family from the Pharming company 
background. So Postma told me: ‘You have to speak to Prosensa.’ And they 
told Prosensa people: ‘You have to speak to Gert-Jan van Ommen.’ The patient 
association person from the Netherlands was Elizabeth Vroom, who founded 
and ran the Duchenne Parent Project, both in the Netherlands and later also the 
international one.172 They had been funding us already from the beginning; they 
actually provided the funding when we didn’t get the money from the UK. So it 
was really a sort of patient/company/scientists confluence. In fact, I’ve been sailing 
with Francesco in 1986 in the Bay of Cagliari, so we knew each other for a long 
168 Prosensa Therapeutics was founded in 2002 and was acquired by BioMarin Pharmaceutical Inc in 2015; 
see www.biomarin.com/about/history/ (accessed 13 January 2017). Interestingly, after a negative review 
by the Food and Drug Administration (FDA) in early 2016, BioMarin announced the withdrawal of the 
Market Authorization Application for Kyndrisa™ (drisapersen; PRO051) in Europe (31 May 2016); see 
www.ema.europa.eu/docs/en_GB/document_library/Withdrawal_letter/2016/06/WC500209201.pdf 
(accessed 15 March 2017).
169 Professor Jacques H van Boom (1937–2004) was Professor Emeritus of Bioorganic Chemistry at the 
Leiden Institute of Chemistry; see van der Marel and Ploegh (2004).
170 See, for example, Peerenboom (1998).
171 The CMSB is a joint activity in genomics and bioinformatics of six institutions: Leiden University 
Medical Center, Leiden University and TNO in Leiden, VU University Medical Center and Free University 
in Amsterdam, and Erasmus MC in Rotterdam. The Centre was established in 2004 and is directed by 
Professor Gert-Jan van Ommen; see www.cmsb.nl (accessed 13 January 2017).
172 Elizabeth Vroom was President (1994–2015) and she is now Director of the Duchenne Parent Project in 
the Netherlands; see www.duchenne.nl (accessed 13 January 2017). She is also Chair of the United Parent 
Projects Muscular Dystrophy; see www.uppmd.org/uppmd/board/ (accessed 13 January 2017).
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time, and it helps that you can get along very well. So actually that helped, and 
there was a very open atmosphere. People agreed to disagree on several things, 
on the backbone, on the muscle, and on this and that, but, ultimately, I think 
that very often when people are doing these complex things, you find that some 
results are at odds with other results, but it doesn’t mean that one is wrong; it only 
teaches you when you find the differences that there’s something to be found out 
still. And so that was the first step.
Gait:  I think that I’d like to just comment on Francesco’s point about suddenly 
the morpholinos becoming available, because there’s a history here that 
the company, AVI BioPharma as it was then called, was in difficulties: the 
morpholino chemistry had been foundering even though it is, in my opinion, 
wonderful chemistry. It’s just because the management had not really found 
a good application, and it was only when they took over the small company 
of Ryszard Kole called Ercole,173 which he’d founded in the University of 
North Carolina, that AVI BioPharma suddenly realized the potential of splice 
switching and exon skipping, and then could make the liaison with Francesco. 
But, indeed, I think that the clinical trial work that Francesco did here, on the 
first trials on morpholino, really did prop up that company at that time. I think 
173 Ercole Biotech (founded in 2002) was purchased by AVI BioPharma (later known as Sarepta Therapeutics) 
in 2008; see also note 159.
Figure 16: Left to right: Dr Koichi Mikami, Professor Bert Bakker (with microphone),  
Dr Michael Gait, Professor Victor Dubowitz, Professor Kate Bushby,  
Professor Shirley Hodgson, and Dr Rosaline Quinlivan
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that was right. They’ve since got many other things and changed management 
several times, and changed name, and so they’re all fine now. But, certainly, 
there was a very difficult time and it was due to the takeover of Ercole, and 
Ryszard Kole actually had a lot of influence on why the morpholino chemistry 
was going, just in the same way as Gert-Jan here had influence over starting 
in Leiden with the company Prosensa. So these, essentially, were very small 
academic start-up companies that then progressed into the two styles of 
chemistry, which are now prevalent today, which will clearly be taken over by 
newer chemistries. There are many of these now being developed, and so there 
will be further phases here. 
Temple:  So there are at least two different lines of chemistry that have now 
branched into two different ways of taking this forward?
Gait:  I think there are two styles of chemistry, which give you different 
opportunities, and those are both being looked at now. However, there are 
further chemistries; for example, a Swiss chemistry from Christian Leumann174 
called the tricyclo-nucleotides. They look terribly promising and quite 
exciting too, and are being developed in France with Luis Garcia’s group175 
as well, which, I think, has tremendous opportunities.176 So, I think there are 
several new chemistries. The Japanese also have new chemistries that they’re 
looking at as well,177 so there will undoubtedly be many more opportunities 
for new chemistries with improved in vivo properties, but the two initial ones 
(2'-O-methyl phosphorothioate and morpholinos) were the points of entry into 
the field, and made clinical trials possible.
Temple:  If you were a newly diagnosed child now, would most people go into 
clinical trials with one of these if they had the right deletion?
Gait:  Bear in mind that we’ve only got about six or seven exons where it’s 
commercially possible to be developing a particular oligonucleotide for patient 
treatment. For so many patients who have much rarer mutations, it’s going to 
174 Professor Christian Leumann is Professor of Bioorganic Chemistry and Rector at the University of Bern; 
www.unibe.ch/university/organization/executive_board_and_central_administration/rector_s_office/prof_
dr_leumann_christian/index_eng.html#pane298055 (accessed 13 January 2017). 
175 Dr Luis Garcia is Director of Research at the Université de Versailles St-Quentin-En-Yvyelines/Université 
Paris-Saclay.
176 Goyenvalle et al. (2015).
177 See, for example, Surono et al. (2004) and Yagi et al. (2004).
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be very, very difficult for an oligo to get into clinical trials. But if you’re lucky 
enough to be in the 60 per cent of those main groups, then, I think, you do have 
a good chance of being able to get into a clinical trial. 
Bushby:  I just wanted to comment specifically on the clinical trial side. I think 
that one of the things that has been amazing – and you’ve heard already from 
Gert-Jan and Francesco – was that the patient organizations have been partners 
in this endeavour right from the very start, and so communication hasn’t 
always been as good as it could be with some of the bigger companies who 
have been involved along the way; but in essence, the communication between 
the scientists – and certainly with the small companies – has been excellent. So 
the patient organizations have really partnered with us in a very real way, not 
only in areas such as patient registries, which we now have under the TREAT-
NMD banner as a resource,178 but also in developing new outcome measures 
and understanding how the disease progression can be mapped, and so forth. To 
come to the access of patients to studies: this has been something which we’ve 
been able to address systematically with the patient organizations through the 
use of registries and so forth, so that patients are identifiable by their mutation 
through the registries, and you can therefore reach out directly. And then, the 
patients who might be eligible for a specific study, can make contact with the 
relevant trial sites. Certainly, up until now, the problem hasn’t been the patients’ 
willingness or ability to participate in trials; the problem is becoming now in 
the field that we don’t have enough sites that are good enough to run all the 
studies that are currently on offer. So, for example, we now have, I think, 10 
or 11 open studies in the UK – not all on exon skipping, of course – but this 
has now led to a bottleneck at the other end, which is that there just aren’t the 
trial sites that are experienced to allow patients access to all the studies that they 
could have access to.
Temple:  We need to come back to why it’s difficult.
Partridge:  One of the aims here was to look at the relevance of the genetic 
discoveries to what’s happened subsequently, and two of the things that 
happened really is, I guess, that clinical patients, human patients, could be more 
closely defined in terms of actually being a Duchenne or a dystrophinopathy. 
And it also verified the animal models. So we worked for a long time on the 
178 TREAT-NMD is a network of neuromuscular research that maintains a Global Registries for Duchenne 
muscular dystrophy and spinal muscular atrophy; for more information on these registries, see www.treat-
nmd.eu/resources/patient-registries/global-registries/introduction/ (accessed 13 January 2017).
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mdx mouse in the hope that it was going to be a relevant model, but it wasn’t 
until the gene was identified that we knew we were working on a model that 
was relevant, at least genetically, to Duchenne and Becker; and likewise a dog.179 
There’s a dog that was identified and the mutation specifically described, and 
that’s one where you’ve got to skip two exons, for instance, if you’re going to do 
exon skipping, and it’s been used – that dog has been used for the exon skipping 
studies for gene therapy. So direct delivery of mini genes has not been much 
talked about, but based on the Becker patients with big mutations. Also with 
cell therapy, the idea of cellular grafts has also been tried on the mouse and the 
dog, and it’s a great comfort to know that we’re dealing with things that are 
actually relevant to the human disease, and those models weren’t available prior 
to the identification of the gene.
Dickson:  I just wanted to comment on a similar point. We have focused on 
exon skipping to a certain extent, but the wonderful work that was described in 
the first half of the meeting that gave us the structure and the sequence of the 
gene has also led to a whole series of potential new therapies being developed: 
you know, exploiting utrophin, for example. 
Temple:  Tell us about utrophin; that’s a very interesting story.
Dickson:  Well, I’m sure that if Kay Davies was here she would tell you all 
about it. But utrophin was initially discovered based on the observation of 
an unexpected embryonic transcript in Northern blots that were probed with 
some of the probes that were developed for dystrophin.180 Then isolating that 
transcript from an embryonic muscle cDNA library, it turned out not to be 
some alternatively spliced form of dystrophin, which is what we thought it was 
going to be originally, but it turned out to be a completely different gene and 
product, utrophin, and present in many, many tissues. In a sense, the cloning 
of the dystrophin gene led to the discovery of utrophin, and utrophin itself is a 
therapeutic target in a clinical trial for Duchenne. So that’s one area. Of course, 
a second area is the one that Terry [Partridge] has mentioned. When you have 
the sequence available of a gene, we can now begin to think about what is the 
more classical gene therapy approach where we try to restore a whole genetic 
structure into the tissues of the cells of the patient. This was something which 
was initially attempted many years ago using a full-length dystrophin cDNA and 
179 See, for example, Valentine et al. (1986).
180 Helliwell et al. (1992) and Pearce et al. (1993).
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delivering a plasmid vector to skeletal muscle.181 But inefficiency was a problem. 
Nowadays, there’s some very good preclinical evidence in various Duchenne 
muscular dystrophy animal models using adeno-associated virus (AAV) vectors 
that perhaps will lead to an effective version of that type of classical gene therapy, 
potentially for Duchenne muscular dystrophy.182 So I just wanted to make those 
two points. The last thing really that I find rather interesting is that, in a sense, 
the steroid treatment we’ve heard about – and I don’t know, Eric [Hoffman] 
may have a further comment on that – but also other small molecule therapies 
that are being developed for Duchenne muscular dystrophy right now, and are 
looking very promising.183 You have to ask yourself, apart from diagnosing the 
patient, would knowledge of the genetics and gene sequences in Duchenne 
muscular dystrophy have made any difference to the trials that have proved 
steroids to be particularly effective, or on the development of new steroids or 
anti-inflammatories and the like that are coming through the system? So, the 
genetics has given us some very interesting new leads into therapy, but I think 
many of the new therapies – small molecule drugs that are coming through – 
maybe don’t owe anything to the actual knowledge of the genetics.
Temple:  Although it always gives you diagnostic certainty, doesn’t it?
Gait:  I wanted to mention small molecules because, first of all, you’re forgetting 
that there’s already one small molecule that the clinic had approved: ataluren 
(Translarna™) for nonsense read-through, for the small number of patients 
with point mutations in Duchenne that go with nonsense read-through.184 And 
that is currently being considered for availability as a drug in the UK right now.
Temple:  Tell us more about that.
Gait:  Well, it’s potentially available, let’s put it that way. I think others could 
tell you more in detail. However, the same company, which is a small company 
in the United States in New Jersey, PTC Therapeutics, is also developing small 
molecules for particular splicing events in several of these diseases, including 
181 Acsadi et al. (1991).
182 Mendell et al. (2010).
183 Heier et al. (2013); Professor George Dickson added: ‘They have come about without the use of gene 
sequence information.’ Note on draft transcript, 2 February 2016.
184 Ataluren (PTC124; TranslarnaTM) is produced by PTC Therapeutics and has received market authorization 
from the European Commission to treat patients with nonsense mutation Duchenne muscular dystrophy; 
for more details, see www.ptcbio.com/en/pipeline/ataluren-translarna/ (accessed 13 January 2017). 
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spinal muscular atrophy and in Duchenne muscular dystrophy.185 What they 
are finding, in fact, is that individual splicing events in particular systems are 
actually not entirely identical, and probably have some different proteins making 
up those splicing events, which give them a unique characteristic that may allow 
small molecules to actually be discovered by a discovery process, which is now 
being automated and robotized in order to find small molecule leads for specific 
splicing events. I think that’s quite exciting: that you do need knowledge of the 
nucleotide sequence and the splicing event at that unique sequence, so that 
small molecules do owe a lot even so to the genetic understanding.
Temple:  That’s true. Tell us a little bit about how difficult it is to do these 
clinical trials. Why are there so few places that can do it?
Bushby:  I guess the first issue is about the rarity of the conditions, and 
Duchenne is rare. However much it is one of the most prevalent conditions we 
see in our neuromuscular clinics, it is nonetheless a rare condition; therefore 
concentration of expertise outside very good centres is often lacking. Actually 
having centres where people have a good body of patients and good training of 
their physios, and so forth, who are going to be able to do these assessments, is 
a real issue. Then, of course, alongside the rarity is, can you actually identify a 
body of patients to participate? Even if you have a particularly good centre, have 
you got the pool of patients who could go to that centre in enough numbers 
to make it worthwhile opening it up as a trial site? Then there are sort of non-
site-specific, and non-rarity-specific, issues – although they often are related 
to the rarity – which are that when we started, we really had no idea about 
what kind of outcome measures we might need for studying Duchenne. We 
thought we knew the condition very well, we understood the natural history, 
we knew that patients went off their feet by between this age and this age, but if 
people came to us and said: ‘What about an actual measure to show progression 
in six months or a year?’ Apart from manual muscle testing or quantitative 
muscle testing – which a synergy group had developed – we didn’t have any 
really very good ways to demonstrate progression. What the regulators began to 
tell us was that they weren’t that interested in muscle strength, because muscle 
strength is something which, if you talk to somebody about gaining this much 
in strength, what does it mean clinically, how does that translate to what a 
patient experiences? So we were very much pushed into the position of trying 
185 See, for example, Welch et al. (2007). 
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to develop and validate scales that had clinical meaningfulness, where you could 
actually say: ‘Okay, this much gain in function will predict that you don’t lose 
ambulation over this length of time.’
Temple:  Again, leading the way really.
Bushby:  Well, it was an interesting discussion, because you talked about ataluren 
and Translarna™, and that company, PTC, was the first one to set up a big, 
large-scale study and they did it – to a certain extent with our advice – but to 
some extent they also had to take the advice of the regulators, and so on. And 
so, we’ve ended up with the six-minute walk distance as a primary outcome 
measure for all of these studies in Duchenne. I think it’s been really quite well 
established that, yes, you can map progression in six-minute walk distance, but 
there are also many, many pitfalls of potentially using this test, and whether it 
actually measures what we’re interested in is something that is very much in 
question. 
van Ommen:  I wanted to connect this point with a point that you mentioned 
much earlier with the Bayesian statistics. Because the issue here was that 
the regulatory authorities in this type of analysis, and especially when large 
companies like GSK (GlaxoSmithKline) or so are involved, typically they 
have these hard and fast rules about P values for the outcome and meeting 
primary objectives. The P value should be 0.05, and if you have two trials 
that are almost the same, and you want to jointly analyse them then this is 
called a ‘meta-analysis’ and your P value has to be 0.025. But the trick is that 
if you have one person dropping dead in a thousand, it means that you have 
thousands of people dropping dead with your drug. And so, still this penny 
hasn’t dropped. But it’s also a very difficult field that is still hotly discussed – 
this community is prepared to take phenomenal risks. We talked about people 
that were considering a 10 per cent risk on a double recombinant as a takeable 
risk, or a 5 per cent risk and so on. Because they stare a serious disease in the 
face, all the time – their life is filled with it – and that’s completely different 
from the type of P = 0.05 statistics, because that means that you have a chance 
of less than one in 20 to be wrong. I think that in this rare disease community, 
that type of cut-off would mean that you could give up developing any 
therapy for the rarer Duchenne mutations, for well, almost anything except 
for spinal muscular atrophy, and cystic fibrosis, and Duchenne, and a few 
more, and then you’re done. So, really, you must project this against getting 
better outcomes, getting better biomarkers, also not, say, false readouts and 
lifestyle and so on, but to integrate that into a sort of patient-defined and 
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patient-centred outcome, which is meaningful to patients, and at the same 
time can be accepted by the regulators; but that certainly it is not going to be 
a 0.025 P. 
Temple:  No, with rare diseases, it is always the problem.
Muntoni:  I would just second and continue this. Starting from one question 
to Kate of why it’s difficult to do this trial. Well, firstly, because there are not 
too many Kate Bushbys, and Ros Quinlivans, and there is a clear issue about 
capacity, especially when you come to some of the early interventional trials.186 
We were actually here in this room at a meeting with EMA (European Medicine 
Agency) to discuss clinical trial design for Duchenne muscular dystrophy. I think 
it was in this room, in June 2014, and then we had a subsequent meeting hosted 
in London at EMA earlier on this year, so we are an active community. Again, 
talking with each other, with the patient community, and with the industry to 
understand what are the things the regulator wants. The regulator is increasingly 
pushing us both into what is clinically meaningful; that is absolutely right. At 
the same time, how can we measure things in a non-invasive way, if we can? 
Unfortunately, up to now, for many of the primary biochemical or secondary 
biochemical outcomes, we need to do a muscle biopsy in these children; ideally 
we’d like to do multiple muscle biopsies, because we would like to see whether 
dystrophin’s been restored, how much there is. This is messy, unfortunately, 
because it’s painful and also, apart from the pain, the distribution of the response 
is not completely uniform, therefore you cannot have a completely clear answer 
to your question.
So, increasingly, we have been asked to look into non-invasive ways: for example, 
muscle imaging as one of the outcome measures. I certainly have a European 
grant, together with a number of sites, including Newcastle, to look at the 
new antisense oligonucleotides for exon using also muscle magnetic resonance 
imaging (MRI) as one of the key outcome measures. But that automatically 
restricts the number of sites where this can be done; it’s not straightforward 
to have muscle MRI consistency. Well, it’s never been done before for muscle 
so it can be done in a small setting with highly trained people, it’s not very 
easily done unless there is an academic centre behind that particular paediatric 
neuromuscular group. So, paradoxically, apart from Kate Bushby and Ros 
186 Professor Francesco Muntoni added: ‘In addition, there is relatively little experience in this field for 
clinical trials, as until recently there were no drugs to be studied. In this respect the interaction with 
regulatory authorities has also evolved in recent years.’ Note on draft transcript, 14 February 2016.
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Quinlivan equivalents, I think what is behind the bottleneck, is a university, 
imaging, and what allows us to move further than just looking at the patient 
and looking how long they walk for six minutes. That, I think, is a bottleneck. 
I thought I understood Duchenne reasonably well and then you start to realize, 
once you start to look really with very precise spectacles at the natural history 
study, the fact that these patients do have different trajectories, and that what it 
means is that it is really unsatisfactory when you can only treat a relatively small 
number of patients. You would like to know: ‘Is the trajectory of this patient 
really being influenced by what I’m doing, or am I just by chance picking up 
five patients who would have done well anyway?’ So there is also a lot of work 
on looking at what modifies the disease, and a lot of actually recent work, again 
collaborations. We are involved in a collaboration with Eric [Hoffman] on the 
other side of the Atlantic, and maybe you might want to say a few things? 
Hoffman:  I think Francesco is talking about understanding the disease trajectory 
and the variability between patients. We’ve talked about Becker versus Duchenne. 
Duchenne is relatively homogenous, it is out of frame missing dystrophin, but 
you still see variability in both onset, severity, trajectory, and the central nervous 
system involvement. And that complicates clinical trials, because that creates this 
noise in which it’s more difficult to see an effect if different patients are acting 
different anyway. So genetic modifiers – that work is going well in multiple 
groups. To use the large natural history studies that Kate mentioned, where you 
can really look at phenotypes, have patients well phenotyped, their strength, their 
gross motor function, and then superimpose genetic polymorphisms that exist 
in everybody to see what modifies the disease progression. Again, as Francesco 
mentioned, that work is going reasonably well through collaborations, so you 
can find these individual polymorphisms that fit into our understanding of the 
disease pathogenesis as well. You know, what’s going on in the muscle? How do 
these other genes influence the muscle reaction to that? 
Then one other thing that is mentioned earlier that cross-references another 
approach to small molecule drugs, is trying to go back to glucocorticoids. 
Even in the original Nobel speech in 1950,187 it was said that you’ve got to do 
something about the side effects, and you heard from Victor and others that, 
for many years, the delay of uptake of glucocorticoids was because of the side 
187 The 1950 Nobel Prize in Physiology or Medicine was awarded jointly to Edward C Kendall, Tadeus 
Reichstein, and Philip S Hench ‘for their discoveries relating to the hormones of the adrenal cortex, their 
structure and biological effects’. See www.nobelprize.org/nobel_prizes/medicine/laureates/1950/ (accessed 
13 January 2017).
The Therapeutic Implications of Muscular Dystrophy Genomics
72
effects. One of the best-studied side effects of glucocorticoids is muscle weakness, 
where you have what’s called the FoxO pathways that are directly regulated by 
glucocorticoids, and directly cause muscle wasting.188 So is what we see in the 
strength increases in Duchenne really a sum of maybe anti-inflammatory minus 
muscle weakness as a side effect? Which suggests that if you can get rid of the 
side effects, you might not only reduce the burden of side effects but possibly 
also increase efficacy.189 So glucocorticoids are complicated. You have to peel 
away – chemically – the many different layers of the onion, but, I think, that’s 
been successful, it looks like it, and that’s now going into Duchenne clinical 
trials with Kate’s help, and the European Union, and many foundations helping 
to move that through.
Sturdy:  I just wanted to pick up on something Kate said a little while ago about 
registries, because it seems to me as though registries are hugely important both 
in terms of making clinical trials possible, and also in terms of gathering the 
natural history of the disease together. I just wondered: is there a history of 
registries that we ought to be taking into account here as well?
Bushby:  Well, there are two different classes of data collection projects, which have 
been going on. One is the big natural history studies of which Eric [Hoffman] 
has led probably the biggest one in the Cooperative International Neuromuscular 
Research Group (CINRG) for many years;190 very well-funded, well-supported, 
large cohorts of patients, followed as if they’re in a trial. So that’s a very valuable 
data set. We have a data set here in the UK, which we’ve been working on with 
Muscular Dystrophy UK for many years, the North Star database, where now 
there is a network of 19 centres across the UK who collect the same data.191 We 
188 The forkhead box O (FoxO or FOXO) family of transcription factors includes atrogenes (genes involved 
in atrophy) that are triggered by glucocorticoids in the muscles, leading to proteolysis and atrophy; see, for 
example, Schakman et al. (2013).
189 See note 183.
190 The CINRG, founded in 1999 as the Clinical Research Arm of the Duchenne Muscular Dystrophy 
Research Center and the Research Center for Genetic Medicine at the Children’s National Medical Center 
in Washington, DC, is now a global, state-of-the-art clinical research network that is undertaking and 
facilitating clinical studies in neuromuscular diseases; see www.cinrgresearch.org/cinrgnetwork/description.
cfm (accessed 13 January 2017).
191 The North Star database is a national database for Duchenne muscular dystrophy, established in 2006, and 
is – along with the North Star clinical network – part of the North Star Project that is run at the Dubowitz 
Neuromuscular Centre at Great Ormond Street Hospital; see www.gosh.nhs.uk/medical-information/
clinical-specialties/neuromuscular-information-parents-and-visitors/about-us/north-star-project (accessed 
13 January 2017).
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did this way back with leadership from Francesco and Adnan192 saying: ‘Right 
if we’re going to use steroids in the UK, we need to be able to monitor how 
it works.’ So the physios went away and developed a scale that is now used in 
trials as well, the North Star Ambulatory Assessment. We followed something 
like 700 or 800 patients, but just in clinical practice, so not with the depth of 
data collection and monitoring the CINRG study does. There are several other 
natural history studies, which are really helping us to understand the history of 
the disease. On the other side, when we got the TREAT-NMD grant – which 
was a Network of Excellence development grant awarded by the European 
Union in 2007 – we decided that one of the biggest priorities with enabling trial 
readiness was patient identification through registries. We worked on a sort of 
federated system whereby individual countries, often with patient organization 
support, sometimes with academic support and/or a mixture of the two, would 
set up a registry in their own domain, but they would be using a minimal data 
set that would be in common across the different data collection methodologies, 
and which would then be able to be aggregated, for example, for enquiries from 
industry. This was a very successful model insofar as we’ve now got registries in 
about 40 different countries, all collecting that minimum core data set, and used 
widely by industry and academic groups, to identify patients for studies and 
identify, for example, areas. We’ve done a big health economic study through the 
registries, we can use it for patient preference studies, we can use it for devising 
new methods for outcome assessment, especially patient-reported outcomes. 
That’s now being widely used by industry so, for example, all of the companies 
who want to identify patients with a specific deletion, will come and they’ll say: 
‘How many patients are in the registries who are still ambulant, who are on 
steroids? And we want to know for the whole world or we want to know for these 
particular countries.’ So that has been, I think, a very powerful initiative. It has, 
again, been done very much in partnership with patient organizations, and it’s 
frequently patient organizations who run the registries and they come together 
on an annual basis to curate a meeting, to discuss good practice, and their good 
practice around data sharing, good practice around data collection, and so forth. 
That’s now extended to other diseases as well, which is quite a powerful model.
Temple:  Just to add a comment there. We have heard quite a lot of things that 
are really interesting about Duchenne, so I remember in the late 1980s we had 
a Duchenne muscular dystrophy registry, and I would say that led the way for 
192 Dr Adnan Manzur is a Consultant Paediatric Neurologist at Great Ormond Street Hospital, and the 
clinical leader for the North Star Project.
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lots of other diseases. There are very few that have been going for that long. 
We’ve also been hearing about how you’ve brought treatment into clinical trials 
relatively early, but what you’re talking about now is personalized medicine, 
showing how incredibly difficult it is. Sometimes rare diseases really do show 
how hard it is to personalize medicine, because not only do you need to get 
drug company involvement, but the great variability that we’ve got between us 
all means it is so difficult, when you’re down to a personal level, to tell whether 
your drug is any good or not. So, I think it’s quite interesting that all of the 
things that you’re describing are just what everyone’s got in store for them, 
whatever disease they’re talking about when we try and apply personal medicine.
Bushby:  I think it’s absolutely true, and when you think back to how long ago 
the dystrophin gene was identified, we have got one EMA approval, conditional 
approval, for one drug, but that’s it. All the other benefits that have come to the 
patients over this same period actually have come through the good application 
of basic medical techniques and so forth. So I think we have seen an enormous 
advance in what we understand and advances in what we can offer, and advances 
in the trials that we can deliver, but our next challenge is now with the funding 
models and with the regulators and the payers because you know EMA is 
approving ataluren (Translarna™) conditionally in Europe and it’s available in 
France, Italy, Germany, Greece, and Spain.193 But in the UK, it’s going through 
193 See note 184.
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the NICE appraisal, which is, you know, going to be the next challenge. If you 
really think that Genomics England194 is going to bring treatments for every rare 
disease, look at how long it’s taken us, and although we’ve made mistakes along 
the way, it hasn’t been totally a disaster.
Quinlivan:  The other challenge we are all going to face – well, patients are 
going to face – is the high cost of these drugs, because for rare diseases they’re 
not going to be high-output drugs for the company, so the costs are going to 
be high. 
Temple:  They are trying to work out a completely different model, aren’t they?
van Ommen:  I think there’s still also one hidden message for Duchenne to the 
rest of the diseases, and perhaps also the common diseases, and that is, because we 
are mechanistically interested in the diseases, we tend to focus on the people who 
are sort of exemplarily ill, to find the mechanisms. But, in fact, if you think back 
to Duchenne and Becker, what it actually also has told us is that in other diseases 
we should also look at people who are unusually healthy, because that very often 
will show us a way towards a therapy. If you have people who should be ill but 
aren’t, then usually they are sort of genetically compensated. Somewhere else 
there is a wiring cut or something else that prevents them from becoming ill, and 
that was the case in Duchenne; it was Becker that prevented them from being 
ill. Why? Because it turned out that they were fortunate as to having a proper 
reading frame. In many diseases there are 1, 2, 3, 5 per cent of people that should 
be ill, but are not. Typically, that is because somewhere else something has gone 
wrong, and that has actually compensated the disease process. That should be 
a lesson for the pharmaceutical companies, because pharmaceutical companies 
incidentally, in my opinion, are better at breaking things than repairing them. If 
we find out what is broken in those people, that prevents them from becoming 
ill, then it proves a way that is naturally tried, like Becker, to circumvent the 
disease. Now it will be different when you suddenly apply medication or when 
these people have it from birth, but I really think that in many of the common 
diseases and the rare diseases, you should actually focus more on the people that 
escape being ill, and that is why you need the big biobanks, because for that you 
need like 50 people that are similarly not ill to derive a mechanism. 
Dubowitz:  Just a very important point that I was also going to raise at some 
time and I originally was inspired into this way back in the 1950s when I used 
to go to lectures advertised in the British Medical Journal at the Royal College 
194 See note 82.
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of Physicians and heard Finkel talking about childhood leukaemia, acute 
lymphoblastic leukaemia in childhood. He was just starting a system of cycling 
therapy for the first time, and he was picking out patients who seemed to be 
unusually responsive to an individual therapy. And this is how the whole business 
of cycling therapy started in a way. ‘Treasure your exceptions’ was the slide he 
had, which I have quoted ever since. Now I’m still puzzled why the mdx mouse 
is not weak. It’s said to be a model for Duchenne, but it hasn’t got Duchenne 
dystrophy. It’s got no dystrophin, they say it’s a small animal, but that doesn’t 
carry any water, because the congenital dystrophy mouse is very weak. I’m also 
fascinated by some of the patients I’ve seen, and there’s one I’ve been following 
now for 10 years who, at the age of four, had absent dystrophin, out-of-frame 
mutation, dystrophic muscle, and no clinical weakness. So no four-year old I’ve 
seen before was devoid of any signs, and had Duchenne dystrophy laboratory-
wise. There’s just recently been a publication of a new colony of dogs; the Golden 
Retriever dog is comparable to Duchenne in severity, absent dystrophin, out-
of-frame mutation. There’s a new colony that’s got no dystrophin, they’re still 
looking for the mutation and is clinically, practically normal.195 So here are 
models, exceptions for us to look at and ask ‘Why?’ I mean, it may just be gene 
modifiers, but in some of them it’s so tremendously different; it’s not just a little 
bit better, but it seems to be almost devoid of the clinical problem. Originally, 
the distinction between Duchenne and Becker was really an artificial one based 
on the studies of the loss of ambulation, so the 95th centile of loss of ambulation 
was 12 years approximately – so that was the limit of Duchenne. The range of 
Becker was very much wider and, of course, there were cases already found with 
an out-of-frame mutation who were doing better and shown to have automatic 
splicing. So, basically, I think the whole range of Becker variation is an important 
one, and there’s, of course, a transitional overlap between sort of intermediate 
cases who walked till 13 or 14. So, I think, we’ve got to look at all of these. But 
certainly, the absent dystrophin is worth looking at.
Partridge:  So two points really. One of them is the modifying factors. If you 
breed the original X mutation on to other backgrounds, it changes the pathology, 
so we’ve been looking at one that two other groups have been looking at, which 
is breeding it on to the DBA/2J background, where it does indeed get weak, 
it loses muscle. It doesn’t do all the things you might expect of it, because, 
although it’s weak and loses muscle, both the amount of degeneration and the 
amount of regeneration go down. So it follows a quite different pathway and 
195 Ambrósio et al. (2008).
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this is an example of the sort of modifying factor you can begin to look at in the 
mouse more easily than any other model system.196 Then, the second thing is the 
rarity of Duchenne. From the point of view of, say, a gene replacement therapy, 
all Duchenne cases could be looked at as pretty much a single entity, a rare 
entity. But if you were looking at it from the point of exon skipping, it’s a whole 
subset of rare entities within the original entity. So although exons 51 and 53 
and 44 and 45 may well be addressed by pharmaceutical companies at some 
stage, all the rarer exons would never be addressed, and they won’t be addressed 
firstly because you couldn’t set up a statistically meaningful experiment around 
them, and secondly because there won’t be the finance for them. The only way 
that people, families with children with those rarer skippable exons would ever 
get into that scheme would be if they actually raise their own funding for it. 
Temple:  Which is very worrying, isn’t it? Now I think that this is the moment 
where we have a chance for people that have got something they feel has not yet 
come out, to just say it. This would be a perfect moment to feel you can take 
the microphone. 
Hodgson:  I just want to say a final thing: that so many times we’ve been talking 
about the patient associations and how important they are, and I just think 
that’s something we can bring out, because clearly a lot of this work just couldn’t 
have happened without the patient associations and how helpful they’ve been. 
Temple:  True. That’s very powerful.
Dubowitz:  There’s one point I wanted to raise that worries me and that is 
when the EMA or whatever gives provisional licensing to a drug before they’ve 
completed Phase 3. How do they handle the situation if the Phase 3 study does 
not work or doesn’t show significance? You’ve then got a situation where the 
drug is marketed, it has to be withdrawn presumably, patients are on it and they 
claim to be benefited by it; it seems to me a whole can of worms.
Temple:  Yes, and rare diseases and individual treatments are going to be the norm 
in the future, and we really haven’t got a plan for it. Just in the gene’s defence, 
I do think understanding and being able to tease apart the actual pathology 
has made a huge difference. When I’m listening to you – I’m not saying that 
from a very pragmatic perspective we haven’t made a big impact with regards 
to steroids and these other treatments, which could have come along without 
the knowledge of the gene – but I still maintain that the certainty of diagnosis, 
196 Coley et al. (2016).
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the deeper understanding that we’ve now got, because we do understand that 
the gene and its function, has made a huge difference. I think we must never be 
tempted to think it doesn’t matter; understanding the cause of diseases is such 
a big thing. 
Hodgson:  Just in the gene’s defence also, there’s so much genetic counselling 
that couldn’t have been done without it.
Temple:  That’s very true.
Bushby:  Paradoxically, even though so many of these treatments that we now 
apply don’t need to know the gene, the fact that there is so much tension on 
the gene and the potential therapies that will come from knowing the gene, has 
actually pushed forward the whole treatment paradigm everywhere. So you get 
that kind of kickback effect, I suppose.
Temple:  I do think that one could make a lot out of so much having been learnt 
from this disease that is of relevance to a lot of other diseases. So, I don’t know 
Steve, if there’s anything else you want to add to that?
Sturdy:  Nothing to add of substance, but I’d really like to add a note of sentiment 
just to thank you all. I didn’t get a chance to introduce myself at the start – I do 
apologize for that – but I’m running the History of Medicine project ‘Making 
Genomic Medicine’ out of which came the suggestion to organize this Witness 
Seminar. We put it to Tilli some while back. I’ve never actually attended one 
of these before. I’ve read and I’ve used, as an historian, the transcripts, which 
are absolutely fantastic resources for historians, and this kind of conversation is 
just wonderful for eliciting fantastic data in an historian’s language. But it’s even 
more exciting to be there in the room when the conversation is going on, so it’s 
just been a great privilege to be here and be part of this. So thank you all very 
much indeed for attending and for all your input. 
Tansey:  If I could add to that also my thanks for you all coming and sharing 
your stories, trusting us, telling us all these wonderful things. And you have 
spoken very movingly, I think, of the ideas of collaboration and sharing things. 
Please join me in thanking Steve and his team for having the idea, and Karen for 
her excellent, engaged chairing of the meeting. Thank you very much, Karen. 
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at Boston Children’s Hospital 
and Harvard Medical School as a 
Muscular Dystrophy Association 
Fellow (1986–1990), working on 
the identification of the Duchenne 
muscular dystrophy gene and 
dystrophin protein. He was faculty 
at University of Pittsburgh School 
of Medicine (1990–1998), then 
George Washington University 
School of Medicine (1998–2016). 
He directed the Center for Genetic 
Medicine Research at the Children’s 
National Medical Center in 
Washington, DC (1998–2016). 
He is currently Associate Dean 
for Research, School of Pharmacy, 
Binghamton University – State 
University of New York, co-
founder and CEO of ReveraGen 
BioPharma, co-founder and Vice 
President of AGADA BioSciences, 
and co-founder of TRiNDS LLC.
199 Transcripts of interviews with Professor Hodgson can be found at: http://dx.doi.org/10.17636/01012730 
and http://dx.doi.org/10.17636/01012731. 
Professor Jennifer Morgan
BSc PhD graduated from King’s 
College London with a BSc in 
zoology and did her PhD in 
pathology at Charing Cross and 
Westminster Medical School, 
under the supervision of Professor 
Terry Partridge. After postdoctoral 
appointments at Charing Cross 
and Westminster Medical 
School and at the MRC Clinical 
Sciences Centre, Imperial College 
London, she joined the Dubowitz 
Neuromuscular Group, headed 
by Professor Francesco Muntoni, 
at Imperial College, London, as 
a Senior Lecturer before moving 
to the UCL Institute of Child 
Health as a Reader in 2008 and 
Chair in 2013. She is a Member 
of the muscular dystrophy exon 
skipping (MDEX) consortium 
and is a PI of the MRC Centre for 
Neuromuscular Diseases, whose 
aim is to perform multidisciplinary 
translational research in 
neuromuscular diseases in order 
to reduce the gap between major 
science discoveries and patient 
benefit. Her major areas of research 
are the identification of stem cells 
that contribute to skeletal muscle 
regeneration, and the genetic 
and functional manipulation of 
these cell populations to enhance 
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muscle repair in skeletal muscle 
regenerative medicine and in the 
treatment of muscular dystrophies.
Professor Francesco Muntoni
MD FMedSci (b. 1959) graduated 
in Medicine from the University 
of Cagliari (Italy) in 1984, and 
obtained his Child Neurology 
and Psychiatry specialization at 
Sassari University in 1989. His 
MD was on neurochemical and 
electrophysiological aspects of 
ethanol addiction in rats. He 
originally worked as a child 
neurologist in Cagliari until 
1993, and then moved to the 
Hammersmith Hospital, Royal 
Postgraduate Medical School, 
London. He became the Clinical 
and Research Director of the 
Neuromuscular Centre at the 
Hammersmith Hospital in 
1996, following the retirement 
of Professor Victor Dubowitz. 
His research, at the time, focused 
on the deep phenotyping of 
dystrophinopathies and on 
the genetic basis of congenital 
muscular dystrophy. In 2008 he 
moved with the entire clinical, 
pathology, and research team 
from the Hammersmith Hospital 
to the UCL Institute of Child 
Health and Great Ormond Street 
Hospital for Children, in London, 
to pursue translational research in 
neuromuscular conditions. He is 
the Head of the Developmental 
Neuroscience Programme in the 
Institute and Novel Therapies 
Theme Lead of the Great Ormond 
Street Hospital Biomedical 
Research Centre. He continues to 
be involved in deep phenotyping of 
neuromuscular diseases (with the 
identification of more than 30 new 
disease genes) and the identification 
of novel therapeutic strategies for 
Duchenne muscular dystrophy 
and spinal muscular atrophy, from 
preclinical development to clinical 
trials.
Professor Terence Partridge 
BSc PhD FMedSci (b. 1940) 
graduated in zoology from 
University of London 1962 and 
PhD in 1970. From 1965 to 
1966, he worked in the Muséum 
Nationale d’Histoire Naturelle in 
Paris on the isolation of rodent 
malarias from Central African tree-
rats. In 1967, he joined the newly 
formed Cell Biology Department 
in the University of Glasgow as 
an Assistant Lecturer. In 1970 
he joined the Department of 
Experimental Pathology, Charing 
Cross Hospital Medical School, as 
a Research Fellow, supported by 
the Muscular Dystrophy Group 
of Great Britain. Subsequently, he 
become a Lecturer (1975–1978), 
Senior Lecturer (1978–1989), 
Reader (1989–1992), and Professor 
(1993–1994) in Experimental 
Pathology at the Charing Cross and 
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Westminster Medical School. In 
1994 he was appointed Professor 
of Experimental Pathology at 
the Royal Postgraduate Medical 
School and Head of Muscle Cell 
Biology at the newly formed MRC 
Clinical Sciences Centre, where he 
remained until retirement in 2005. 
In his final year, he took sabbatical 
leave to the Genethon and the 
Pasteur Institutes in Paris, on an 
Award of ‘Chaire International 
de Rechearche Blaise Pascal’. On 
retirement from the MRC in 2005, 
he took up a post in the Center for 
Genetic Medicine at the Children’s 
National Medical Center in 
Washington DC, where he remains 
at present, continuing his research 
on the pathology of muscular 
dystrophy and on the potential 
of exon skipping as a therapeutic 
avenue.
Dr Rosaline Quinlivan
BSc(Hons) MBBS DCH FRCPCH 
FRCP MD (b. 1959) graduated in 
psychology in 1977 and medicine 
in 1980 from University College 
London, and obtained her MD 
from the University of London in 
2010 on work she did to investigate 
the cardiomyopathy of Duchenne 
and Becker muscular dystrophy 
in the 1990s. Her neuromuscular 
training was at Guy’s Hospital 
in London. Her first Consultant 
post in 1995 was in the West 
Midlands as a Paediatrician with an 
interest in neuromuscular disease. 
From 2002, she became a full-
time Neuromuscular Consultant, 
working at Birmingham Children’s 
Hospital and the Robert Jones 
and Agnes Hunt Hospital, where 
she was Director of the Wolfson 
Centre for Neuromuscular 
Disease. She currently works at the 
MRC Centre for Neuromuscular 
Disease at the National Hospital 
for Neurology and Neurosurgery, 
Queen Square, and the Dubowitz 
Neuromuscular Unit at Great 
Ormond Street Hospital, where 
she leads for transition and in the 
management of young adults with 
neuromuscular disease.
Professor Steve Sturdy 
PhD (b. 1957) graduated in natural 
sciences from the University of 
Cambridge in 1979. He took 
an MA in philosophy of science 
from the University of Western 
Ontario, then a PhD in science 
studies from the University of 
Edinburgh in 1987, writing his 
thesis on the life and work of the 
physiologist J S Haldane. He then 
spent seven years as a Wellcome 
Research Fellow in the Centre for 
the History of Science, Technology 
and Medicine at the University of 
Manchester. In 1994 he secured 
a Wellcome Trust University 
Award in the History of Medicine 
at the University of Edinburgh, 
where he has remained ever since, 
86
The Therapeutic Implications of Muscular Dystrophy Genomics – Biographical Notes 
serving from 2006 to 2012 as 
Deputy Director of the Economic 
and Social Research Council 
Genomics Policy and Research 
Forum, and from 2012 to 2015 
as Head of Science, Technology 
and Innovation Studies. In 2013 
he was promoted to a personal 
Chair in the Sociology of Medical 
Knowledge. He currently holds a 
Wellcome Trust Senior Investigator 
Award in Medical Humanities, with 
a project entitled ‘Making Genomic 
Medicine’.
Professor Tilli Tansey 
OBE PhD PhD DSc HonMD 
HonFRCP FMedSci (b. 1953) 
graduated in zoology from the 
University of Sheffield in 1974, 
and obtained her PhD in Octopus 
neurochemistry in 1978. She 
worked as a neuroscientist in the 
Stazione Zoologica Naples, the 
Marine Laboratory in Plymouth, 
the MRC Brain Metabolism Unit, 
Edinburgh, and was a Multiple 
Sclerosis Society Research Fellow 
at St Thomas’ Hospital, London 
(1983–1986). After a short 
sabbatical break at the Wellcome 
Institute for the History of 
Medicine (WIHM), she took a 
second PhD in medical history 
on the career of Sir Henry Dale, 
and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History of 
Modern Medical Sciences at UCL 
in 2007 and moved to Queen Mary 
University of London (QMUL), 
with the same title, in 2010. With 
the late Sir Christopher Booth she 
created the History of Twentieth 
Century Medicine Group in the 
early 1990s, now the History of 
Modern Biomedicine Research 
Group at QMUL. 
Professor Karen Temple
MBChB MD FRCP graduated 
with Honours from the University 
of Birmingham Medical School 
in 1981. She trained first in 
paediatrics in Birmingham and 
London, and after a short period 
at the MRC in the Gambia. She 
became a Lecturer in Clinical 
Genetics at the Institute of Child 
Health, London, and later Senior 
Registrar at Great Ormond Street 
Hospital. In 1990, she moved 
to Southampton as Consultant 
in Clinical Genetics, where she 
and her colleagues, Dr Nick 
Dennis and Professor Pat Jacobs, 
developed Medical Genetics on 
the South Coast and established 
the Wessex Regional Genetics 
Service. She continues to work as 
a clinician. Her research into new 
genetic mechanisms of human 
developmental identified novel 
imprinting disorders changing 
the diagnosis and medical care of 
patients. She is currently Professor 
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of Medical Genetics at the 
University of Southampton (since 
2006), and leads the academic 
unit of Human Development and 
Health, one of four research units 
in the Faculty of Medicine. She co-
leads the Wessex Genome Medicine 
Centre with Professor Tony 
Williams and the Southampton 
Biomedical Research Centre 
bioinformatics group.
Professor Gert-Jan van Ommen
PhD (b. 1947) graduated in 
biochemistry at the University 
of Amsterdam, worked at the 
University of Amsterdam Children’s 
Clinic, and then moved to the 
Department of Human Genetics 
of Leiden University Medical 
Center, which he headed from 
1991 to 2012. He established 
the Leiden Genome Technology 
Center, and the CMSB. He is 
Editor-in-Chief of the European 
Journal of Human Genetics, past 
President of HUGO (1998–2000) 
and of the European and Dutch 
Societies of Human Genetics. He is 
National Coordinator of Orphanet, 
Founding Member of the European 
Biobanking and Biomolecular 
Research Infrastructure (BBMRI) 
and of BBMRI-NL. His 
department has contributed to the 
finding of the gene defects and 
disease mechanisms underlying 
Duchenne muscular dystrophy, 
Huntington disease, polycystic 
kidney disease, hereditary 
neuropathies, fragile X syndrome, 
Rubinstein–Taybi syndrome, 
familial hemiplegic migraine, and 
facioscapulohumeral muscular 
dystrophy. His group performed 
the first prenatal diagnosis 
using DNA markers of a disease 
(Duchenne muscular dystrophy), 
of which the gene was (then) still 
unknown, developed many gene 
mapping and mutation detection 
techniques, the first megabase map 
of a human gene, and pioneered the 
exon-skipping approach for therapy 
of Duchenne muscular dystrophy. 
Further exon skip developments are 
under way for Huntington disease, 
cerebral autosomal-dominant 
arteriopathy with subcortical 
infarcts and leukoencephalopathy, 
and limb-girdle muscular dystrophy 
(dysferlin).
Professor Jan Witkowski 
PhD (b.1947) graduated in 
zoology from the University 
of Southampton in 1968 and 
obtained his PhD in biochemistry 
at the National Institute for 
Medical Research in 1974. That 
year Witkowski joined Victor 
Dubowitz at Hammersmith 
Hospital to carry out research 
using tissue culture to study the 
behaviour and biochemistry of 
human muscle cells. He spent 
1976 with Andrew Engel at the 
Mayo Clinic, Minnesota, and 
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in 1984 was awarded an MRC 
fellowship in recombinant DNA. 
Witkowski took up this fellowship 
with Gordon Peters at the Imperial 
Cancer Research Fund, working 
on oncogenes. In 1986, Tom 
Caskey invited him to run the 
DNA diagnostics laboratory at the 
Institute for Molecular Genetics, 
Baylor College of Medicine, 
Houston. He became Director 
of the Banbury Center at CSHL 
in 1987, and is responsible for 
the topics and organization of 
some 20 meetings each year. 
He has published several books, 
including Davenport’s Dream: 
21st Reflections on Heredity and 
Eugenics, Recombinant DNA with 
Jim Watson, and The Annotated 
and Illustrated Double Helix, a 
new edition of Watson’s classic 
memoir. His latest book is The 
Road to Discovery: A Short History 
of Cold Spring Harbor Laboratory. 
Witkowski is Editor-in-Chief of 
Trends in Biochemical Sciences.
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